

REIMAGINING UROLOGY

FISCAL YEAR REPORT: 2025



 **Health**
UNIVERSITY OF MIAMI HEALTH SYSTEM

DESAI SETHI
UROLOGY INSTITUTE

A Message from Our Leaders

DEAR COLLEAGUES AND SUPPORTERS,

This year marks another exciting chapter for the Desai Sethi Urology Institute (DSUI) — one defined by momentum, new leadership, and a shared vision for the future.

As the founding director of DSUI, it remains a privilege to witness and help guide its continued evolution. I'm also honored to serve in a new capacity this year, having been named chief executive officer of the University of Miami Health System and executive vice president for health affairs at the University of Miami. These broader responsibilities reinforce my deep commitment to advancing academic medicine and create greater alignment between DSUI's mission and the health system's strategic goals.

As a physician leading an academic health system, I bring a clinical lens to every decision — one shaped by years at the bedside and in the operating room. That perspective is essential as we navigate the future of medicine, ensuring that patient care, research, and education remain deeply connected at every level of our organization.

This year's report is grounded in a theme that reflects both our ambition and the demands of a changing world: **Reimagining Urology**. This includes reimagining leadership. I'm

pleased to share that Dr. Mark L. Gonzalgo, a long-standing leader within DSUI, has been appointed chair of the Department of Urology at the University of Miami Miller School of Medicine and UHealth. As vice chair, he played a critical role in advancing our clinical, research, and educational programs. In his new role, he will oversee and integrate these efforts across the department and the Institute. Please join me in congratulating him.

Innovation in our field is accelerating — from robotics and AI to augmented reality and data-driven care models. At DSUI, we believe it's not enough to adopt new tools. We must rigorously evaluate them, integrate them thoughtfully, and lead with the clarity and responsibility that comes with being a top academic center. We are exploring how technology can enhance human care — not replace it.

Our research and clinical faculty are redefining how we diagnose, treat, and prevent urologic conditions — from cancers to kidney stones to pelvic floor disorders. These efforts, strengthened by collaborations across the University of Miami Health System and global academic partners, are being shared on the world stage, from DSUI-hosted symposia to major conferences.

DSUI's rise continues: we now rank 14th in NIH funding nationally for urology — a marker of our scientific progress and institutional credibility. We are attracting top talent,

expanding interdisciplinary programs, and reinforcing our position as a destination for discovery and excellence.

Thank you for being part of this journey. We are proud to share this report with you — and proud to continue redefining the future of urology, together.

Dipen J. Parekh, M.D.
Chief Executive Officer, University of Miami Health System
Executive Vice President of Health Affairs, University of Miami
Founding Director, Desai Sethi Urology Institute
Professor, Department of Urology
Director of Robotic Surgery
Dr. Victor A. Politano Endowed Chair in Clinical Urology
Leonard M. Miller School of Medicine



DEAR COLLEAGUES AND PARTNERS,

It is a tremendous honor to step into the role of chair of the Department of Urology at the University of Miami Miller School of Medicine and UHealth.

What excites me most about this opportunity is the chance to work alongside our exceptional faculty, trainees, and staff to further a shared vision—one that blends clinical excellence, cutting-edge research, and a deep commitment to education. Together, we are **reimagining** what academic urology can be.

At the Miller School and the Desai Sethi Urology Institute, multidisciplinary care and scientific discovery intersect to shape the future of patient care. This environment is rich with collaboration, innovation, and a sense of purpose. It is a privilege to lead and help cultivate that culture.

In this new role, I will continue my work as a surgeon, researcher, and educator—focused on advancing robotic treatments for prostate, bladder, and kidney cancers; mentoring fellows through our urologic oncology program; and overseeing perioperative surgical services at UHealth. These responsibilities keep me connected to our mission at every level.

Having previously served as vice chair, I've had the opportunity to work closely with Dr. Dipen Parekh as he transformed the department and laid the foundation for the Institute. Under his visionary leadership, we've emerged as a national leader in

academic urology. I am deeply grateful for the path he forged and committed to building upon that legacy.

Looking ahead, one of my highest priorities is to strengthen a culture rooted in trust, professional growth, and shared purpose. I believe that when people feel supported, empowered, and aligned, extraordinary things happen—for patients, for science, and for the profession.

The momentum we have built is real—and it's growing. I look forward to collaborating with colleagues across the country and around the world as we continue to elevate our impact and lead urology into its next era.

Mark L. Gonzalgo, M.D., Ph.D., M.B.A.
Professor and Chair, Department of Urology
Desai Sethi Urology Institute
Leonard M. Miller School of Medicine
Executive Director, Perioperative Surgical Services, University of Miami Health System



Inside

Innovation Empowered
Clinical Care 3

Research..... 13

Sharing Our Experience
with AI/AR 22

Meetings of the Minds..... 27

2025 AUA Highlights 31

Education..... 34

Administrative Happenings 41

Philanthropy 43

DSUI Faculty 45

Presentations 48

Publications..... 52



What distinguishes the Desai Sethi Urology Institute from other programs is the seamless integration between surgical care and scientific discovery. Our work in the operating room directly supports translational research through a multitude of clinical trials and registry protocols. This collaboration allows us to ask better questions in the clinic and lab to ultimately deliver better outcomes for our patients.

Mark Gonzalgo, M.D., Ph.D., M.B.A., professor and chair.



Innovation Empowered Clinical Care

MARKET PENETRATION AND GROWTH BY THE NUMBERS

DESAI SETHI UROLOGY INSTITUTE (DSUI) REMAINS THE MARKET LEADER IN MIAMI-DADE COUNTY, REPRESENTING 40% OF ALL UROLOGY SURGERIES IN THE COUNTY. IN BLADDER CANCER SURGERY, SPECIFICALLY, WE REPRESENT 65% OF THE MIAMI-DADE MARKET.

OVERALL, WE INCREASED SURGICAL VOLUME FROM FY24 TO FY25 BY 11%

Innovation Empowered Clinical Care

At DSUI, we are committed to accelerating the integration of new knowledge and technology to improve patient care. This translational approach informs our efforts in the diagnosis, treatment and prevention of urological conditions. This fiscal year

brought significant advancements across all these areas.

The success mirrored in our surgical volume growth is a result of the many efforts highlighted in the following pages.

"What distinguishes the Desai Sethi Urology Institute from other programs is the seamless integration between surgical care and scientific discovery. Our work in the operating room directly supports translational research through a multitude of clinical trials and registry protocols. This collaboration allows us to ask better questions in the clinic and lab to ultimately deliver better outcomes for our patients." Mark Gonzalgo, M.D., Ph.D., M.B.A., professor and chair.

When DSUI faculty remove a kidney or prostate tumor, for example, they often ligate the blood vessels that supply that organ. Since they are occluding and taking them anyway as part of the procedure, just before doing so, they can draw a blood sample directly from these vessels. This offers a snapshot of what's happening locally in the tumor environment.

It's something you cannot get from a peripheral blood draw.

"We are then able to identify thousands of metabolites, thanks to the mass spectrometry expertise of the [Nima Sharifi, M.D., Laboratory](#) (unlike in the past, when

we were limited to a few dozens). These data are combined with imaging and clinical data to uncover potential diagnostic and therapeutic targets. What began as a focus on renal cell carcinoma has now expanded to surgeries for upper tract urothelial tumors and prostate cancer." Pedro F. S. Freitas, M.D., clinical instructor.

In another example of innovation, Laura Horodyski, M.D., assistant professor and associate program director of the DSUI Residency Program, became the first in South Florida to offer transurethral incision with transverse mucosal realignment, a minimally invasive procedure shown to successfully treat nearly 90% of patients with bladder neck contracture and vesicourethral anastomotic stenosis with the first surgery.



Dr. Horodyski (pictured right), a reconstructive urologist, trained with Mayo Clinic's Nick Warner, M.D. (pictured center), who pioneered transurethral incision with

transverse mucosal realignment surgery. Dr. Horodyski and the approximately 26 urologic surgeons nationwide who have trained in this procedure are planning to pool their data and publish outcomes studies in the future. The minimally invasive option replaces the need for major open or robotic surgeries aimed at treating bladder neck contracture, or a narrowing of the bladder outlet where it joins the urethra that can occur post-benign prostate surgery or prostate cancer treatment.

"One of our goals at DSUI is to push the field of urology forward and to be among the first to offer patients the best and most up-to-date types of care. Transurethral incision with transverse mucosal realignment surgery checks boxes for safety, as a minimally invasive option, and effectiveness, for solving a distressing quality of life issue in patients' lives. We applaud Dr. Horodyski for pursuing the training and bringing this to DSUI." DSUI Founding Director, Director of Robotic Surgery, and Chief Executive Officer, University of Miami Health System Dipen J. Parekh, M.D.

Building on Robotics Innovation

Being truly innovative in urology practice requires a constant commitment and willingness to go to the next level, change and adapt—even if outcomes are perfectly acceptable as they are.

An example of that is DSUI's commitment to not only using robotics in urology but also stretching the parameters of robotics innovation.

"Many centers continue to use the da Vinci Xi system. We were among the first academic centers to use that system in 2014. The newest da Vinci, da Vinci 5, enables even better patient outcomes and surgical efficiency." DSUI Founding Director, Director of Robotic Surgery, and Chief Executive Officer, University of Miami Health System Dipen J. Parekh, M.D.

**ROBOTIC-ASSISTED SURGERY
ACCOUNTED FOR ABOUT 17% OF
DSUI'S SURGERIES IN FY25.**

**DSUI'S ROBOTIC-ASSISTED
SURGERIES**

**ROSE BY
19.4%
FROM 2024 TO 2025.**

From Multiport to Single Port

In addition to expanding access to the da Vinci 5 robotic platform, DSUI Professor of Urologic Oncology, Chad R. Ritch, M.D., M.B.A., has earned distinction as one of today's most experienced cancer surgeons in using da Vinci's single port system for prostate and kidney cancers.



As a member of the U.S. regional group Single Port Advanced Research Consortium (SPARC), which shares experiences and outcomes across institutions, Dr. Ritch is committed to optimizing single port robotic surgery outcomes.

The traditional, multiport robots at DSUI incorporate the same tools as the multiport but through one small (less than three centimeters) incision, which potentially improves patient outcomes and results in shorter recovery times. It also allows access to areas in the body with significant scar tissue.

"A patient might be referred to me for single-port robotic surgery if they have had multiple previous abdominal surgeries, for example. So the risk of encountering scar tissue and having damage to the intestine because of scar tissue is higher. Using the multiport, we would have to go through the abdomen. With the single-port robot, one of the common procedures we do is the retroperitoneal partial nephrectomy, which goes in through the back, or flank, as opposed to the front, to remove kidney tumors. It's a similar thing for prostate cancer patients who have gone

through multiple abdominal surgeries who develop prostate cancer. With the single port robot, I can do what is called extraperitoneal robotic prostatectomy and stay away from the abdominal cavity, avoiding all the scar tissue." Chad R. Ritch, M.D., M.B.A., professor of urologic oncology.

In these and other select cases, the single-port procedure offers the same outcomes as a multiport robotic surgery but is safer because of the lower risk of bowel injury and bowel issues, post-surgery. Patients tend to recover very quickly, with minimal pain thanks to the small incision.



Aquablation Update

DSUI continues to see tremendous improvement in treating men with lower-urinary tract symptoms, more than a year since adding the AquaBeam robotic system. The AquaBeam aquablation system is the first FDA-approved surgical robot that automates tissue resection to treat lower-urinary tract symptoms in men who have BPH.

DSUI faculty have done approximately 150 of these procedures, putting our Institute in the top performing aquablation centers in the country.

"Aquablation offers a high likelihood of preservation of ejaculatory function, reduction of erectile dysfunction and maintenance of very good quality of life. It is done in the operating room with a very precise robotic apparatus that allow us to remove obstructing tissue within the urethra in order to allow men to void with a much-improved force of the urinary stream, reduced frequency and urgency and with minimal downtime." Bruce Kava, M.D., professor of clinical urology, director of men's health and president of the American Society for Men's Health.

Transperineal Prostate Biopsy Innovation, Expertise

Prostate biopsies are a common procedure, making constant improvements in technique, outcomes and patient comfort paramount.

DSUI faculty have been performing transperineal biopsy for about four years and are gathering data as they evaluate technology to further improve outcomes. While MRI is commonly used to guide prostate biopsies, our faculty is now using high-resolution micro-ultrasound to improve targeting.

DSUI is one of the few centers in Florida using this advanced technology during transperineal biopsies. It offers real-time, high-clarity imaging that may reduce the need for MRI by better identifying suspicious areas. Our data, as well as a recent randomized trial, show that micro-ultrasound is as effective as MRI in detecting prostate cancer. It also avoids the limitations of MRI fusion—where images are overlapped—by enabling real-time targeting, which may lead to more accurate diagnoses and fewer unnecessary or repeat biopsies.

In addition to micro-ultrasound, our faculty is also evaluating augmented reality (AR) to further improve targeting during prostate biopsies.



“Using AR headsets, we upload MRI images, overlay them on the patient and—wearing the goggles—we can actually see where the lesion is. You can even measure the distance from the probe into the lesion, which helps ensure accurate targeting.” Bruno Nahar, M.D., associate professor of urologic oncology and the Eric and Elizabeth Feder Family Endowed Chair in Urologic Oncology Research at the Miller School. Dr. Nahar is also co-director of Urology on the Beach.

“Adding AR during transperineal biopsy does improve the economy of motion, ergonomics of the procedure and likely makes the procedure faster because everything is where you are looking when wearing the goggles. We are at a point now where we are pushing the technology to really help address current gaps in the field and improve outcomes. We are very excited to see where this goes and have high expectations of the benefits it will bring.” Sanoj Punnen, M.D., M.A.S., M.B.A., professor of urology and vice chair of research.



Beyond HIFU

DSUI has established itself as a leading reference center for focal therapy, particularly with high-intensity focused ultrasound (HIFU), which has proven effective in treating prostate cancer while preserving urinary and sexual function. After publishing the first U.S. series on focal HIFU, our team recently published long-term follow-up results in a high-impact journal and presented them at major conferences, highlighting the importance of proper patient selection. By treating only the cancerous portion of the prostate and sparing normal tissue, focal HIFU offers strong cancer control with excellent quality of life outcomes.

HIFU is one of several energy sources used in focal therapy, but it has limitations—especially in treating anterior tumors. To expand access, we have now incorporated irreversible electroporation (IRE) into our focal therapy program.

“For especially anterior tumors, we have started using IRE, which delivers a very localized electrical current to the area where

the cancer is and that creates micropores inside the cells to destroy cancer cells. This allows more patients—especially those previously deemed ineligible for focal therapy due to tumor location or anatomy—to benefit from a targeted treatment approach.” Bruno Nahar, M.D., associate professor of urologic oncology and the Eric and Elizabeth Feder Family Endowed Chair in Urologic Oncology Research.



Raveen Syan, M.D., associate professor of clinical urology, continues to pursue clinical success and research funding in the fields of stress urinary incontinence, pelvic organ prolapse and overactive bladder.

Dr. Syan and her partner, Dr. Katherine Amin, have increased the number of sacral nerve stimulators they have placed from 141 in 2023 to 219 in 2024. She also started a video urodynamics unit at DSUI.

“The addition of imaging during a urodynamics study improves diagnostic capabilities and provides more information about a patient’s voiding dysfunction.” Raveen Syan, M.D., associate professor of clinical urology



UROGYNECOLOGY AND RECONSTRUCTIVE PELVIC SURGERY (URPS) GROWTH BY THE NUMBERS:

URPS SURGERIES

GREW BY 26.4%

FROM FY24 TO FY25,
WHICH WAS 9% OF ALL
DSUI ROBOTIC CASES IN FY25.

Men’s Health

DSUI has been selected as part of a multicenter collaboration for development of FDA-approved Xiaflex injections to treat Peyronie’s disease.

“As part of this multicenter collaboration with major U.S. centers, DSUI has performed more of collagenase clostridium histolyticum injections than other participating centers and we have contributed more procedures and more patients to the cumulative database. As a result, DSUI was recognized in several abstracts on this work at the AUA and will present data at the Sexual Medicine Society of North America meeting

in October 2025. DSUI is becoming a center of excellence in caring for patients with Peyronie’s disease.” Bruce Kava, M.D., professor of clinical urology and director of men’s health.

DSUI’s survivorship work for men with prostate cancer and sexual disorders following treatment for prostate cancer is being recognized. Several years ago, our faculty developed and [published data](#) looking at a safer and highly effective technique for placing prosthetic devices in many of these men. This technique is now being used by many centers here and abroad. This work was highlighted and recognized at a podium session at the recent Sexual Medicine Society of North America meeting at the AUA.

Expanded Diagnostic Capabilities

We mentioned adding the C-Arm to our clinical services in last year’s report and are happy to report this valuable diagnostic technology has allowed us to add several tests aimed at improving urologic patient care.

Among the new testing options:

- Retrograde urethrogram, or RUG
- VCUG test, or voiding cystourethrogram
- Antegrade pyelogram

DSUI remains committed to integrating advanced technology into clinical practice to improve diagnostic precision, enhance the patient experience and deliver high-quality, accessible care.

DSUI'S CLINICAL EXPANSION

DSUI Expands Footprint at UHealth SoLé Mia Medical Center

DSUI is on a mission to reach more patients with the Institute's high level of patient care. In this fiscal year alone, we've launched the expansive UHealth Doral Medical Center, and we are celebrating the brand-new opening of [UHealth SoLé Mia](#), in the City of North Miami, which represents UHealth's largest outpatient ambulatory project to date and expanded access to academic medicine to the city and its surrounding communities.

[UHealth SoLé Mia](#) is the pillar of modern, high-tech health care in northern Miami-Dade and Broward counties. DSUI has a major presence at this transformative, seven-story, 363,000-square-foot facility featuring 110 exam rooms, 10 operating rooms and 33 clinical cancer treatment units. UHealth SoLé Mia also is a beautiful facility, with the serenity of green spaces and views of the ocean and SoLé Mia's seven-acre Crystal Lagoon, designed to help enhance the patient experience for those receiving extended medical care.



Among the DSUI team members treating patients at the location is accomplished urologist Safwat K. Zaki, M.D., FACS. Recruited from Kettering Health in Ohio, Dr. Zaki led the system's urology service line and robotic program. He completed a fellowship at Cleveland Clinic in renal vascular surgery and another in laparoscopy and robotic surgery at Henri Mondor Hospital in France. He also holds a Ph.D. from Cairo University. His decades of expertise span general urology, endourology, laparoscopy, robotics and oncology.

"SoLé Mia is going to be a cutting-edge urology destination," said Dr. Zaki. "I was among the pioneers to start robotic surgery in the country. The opportunity to bring advanced care to North Miami and work alongside DSUI's exceptional team brought me here."

The Start of Something Great: Doral

Only a year after its opening, our fully-staffed, 160,000-square-foot [UHealth Doral Medical Center](#), is a great success.

Numbers help to tell the story of how this vibrant, South Florida community is embracing access to South Florida's premier academic medicine system.

"We are in the heart of the quickly growing Doral community, offering access to patients who used to have to drive 40 minutes to go to our main campus. Three months after we opened, I was already seeing 25 patients every day. We have since started sending some follow-up patients to our qualified physician assistants to free my schedule and decrease wait times." Rodrigo Lessi Pagani, M.D., assistant professor of urology.


The DSUI team had over 4,000 patient encounters at [UHealth Doral Medical Center](#) within the first eight months of opening.

The only academic-based medical system in the area, UHealth Doral Medical Center offers a full range of urological services, such as general urology, urologic oncology and reconstruction, infertility treatment and men's health, with the latest technology and innovation, including robotic surgery. Fertility

patients at Doral also have close access to the IVF center at the University of Miami, an important fertility center for patients who want to have children.

"We have a state-of-the-art ambulatory surgical center at Doral. The equipment

is top-notch. I've been working in male infertility and doing microsurgery for about 30 years, and I've never experienced a microscope like the one I use for microsurgery at Doral." Rodrigo Lessi Pagani, M.D., assistant professor of urology.




We have a state-of-the-art ambulatory surgical center at Doral. The equipment is top-notch. I've been working in male infertility and doing microsurgery for about 30 years, and I've never experienced a microscope like the one I use for microsurgery at Doral.


Rodrigo Lessi Pagani, M.D., assistant professor of urology, who in addition to infertility, treats a variety of general urological conditions at UHealth Doral.




The DSUI Team at UHealth Doral Medical Center



Dani Papir, M.D.
Urology




Jonathan Katz, M.D.
Endourology



Laura Horodyski, M.D.
Reconstructive Surgery



Manuel Molina, M.D.
Andrology



Ramgopal Satyanarayana, M.D.
Urology



Raveen Syan, M.D.
Female Pelvic Medicine and Reconstructive Surgery



Rodrigo Pagani, M.D.
Urology



Dr. Shah has performed more than 1,600 HoLEP procedures since 2003, trained many urologists in the technique and has published extensively on the topic, including three papers in 2024 alone.

Published studies on the topic of HoLEP include:

[Functional outcomes of single-session holmium laser enucleation of the prostate and high-intensity focused ultrasound in management of patients with prostate cancer and enlarged prostate: results from a pilot study | World Journal of Urology](#)

[Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta-analysis - Bhatia - 2024 - BJUI Compass - Wiley Online Library](#)

[Evaluating the efficacy and safety of Holmium laser enucleation of the prostate in patients with obstructive uropathy attributable to bladder outlet obstruction | World Journal of Urology\]](#)

HoLEP and more

Doral offers access to our faculty's high level expertise in important and state-of-the-art treatment options, including holmium laser enucleation of the prostate ([HoLEP](#)) for benign prostate hyperplasia.

Jonathan E. Katz, M.D., assistant professor of urology, trained under Hemendra Shah, M.D., associate professor of urology, and honed his skills in HoLEP during an endourology-laparoscopy fellowship at UC San Diego. Today, Dr. Katz offers outpatient HoLEP to patients at Doral.

DSUI stands out for its robust clinical trials portfolio. There are many large academic centers that are well known for their large historical databases. However, many of them do not engage in that many prospective clinical trials. Our department has been fortunate to have a dedicated research team and infrastructure that helps us open, streamline and enroll successful clinical trials in prostate, kidney and bladder cancer, in addition to other urological diseases.

Sanoj Punnen, M.D., M.A.S., M.B.A., professor of urology and vice chair of research.




Research

FORGING AHEAD WITH THE SCIENCE

The Desai Sethi Urology Institute continues its rise in the Blue Ridge Institute for Medical Research national rankings, with its current ranking of 14 up a spot from last year.

2023 Ranked #15 \$2,074,130 In Funding	2024 Ranked #14 ↑ \$2,157,903 In Funding
---	---



Our researchers continue to push the boundaries of knowledge and discovery using innovation and novel approaches.

Prioritizing Research Quality

Building our centralized research infrastructure for successful clinical trials has minimized many of the hurdles that deter human studies, such as patient attrition, study noncompliance and more. Rather than delegating research responsibilities to non-dedicated research personnel, who may have limited expertise or bandwidth, we invested in a dedicated, cohesive and complete research team.

Our staff includes:

- A growing team of experienced and highly trained research coordinators, who understand the complexities of the work we do and the meaning behind why we do it.
- A full-time biostatistician who can address any immediate needs for assistance with data analysis.
- A regulatory manager charged with quality management and assurance making sure that anyone involved with

research has the proper credentials and proper training. Protocols that our investigators are developing are also carefully reviewed to ensure they meet institutional, national and international quality standards.

To further streamline and elevate our research capabilities, we implemented a protocol development program that allows investigators to bring study concepts directly to our research team for support in writing and submitting protocols. This has significantly reduced the time it takes to activate new studies.

Through all these combined efforts, DSUI has shortened the time required to write, approve, and implement studies. These improvements have enhanced patient screening efficiencies, and our audits and regulatory reviews have yielded minimal findings—an indicator of the strength of our quality infrastructure.

"The screening process we've implemented at DSUI has meaningfully reduced the burden on clinicians by allowing for better anticipation and identification of eligible patients. It's a model that works, which is why I've recommended adopting a similar approach more broadly." Mark Gonzalgo, M.D., Ph.D., M.B.A., professor and chair.

ACTIVE/IN-PIPELINE
UROLOGY CLINICAL STUDIES:

2024

2025

38

64

PARTICIPANTS ENROLLED IN
CLINICAL TRIALS:

2024

2025

370

509

RESEARCH SUPPORT STAFF

(research admins, data/regulatory
and research coordinators):

2023

2024

2025

6

10

11

Prostate Cancer Clinical Trials: MDSelect and MAST

DSUI faculty are publishing papers related to the National Cancer Institute (NCI)-funded [MRI Based Active Selection for Treatment Trial \(MAST\) completed last year](#). Led by Sanoj Punnen, M.D., professor of urologic oncology and vice chair of research, MAST looked at whether magnetic resonance imaging (MRI) along with MRI targeted biopsy of suspicious lesions is of value in detecting patients who would be likely to require treatment earlier.

Dr. Punnen has been among the authors of these two papers published, related to [MAST: Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST Trial](#) and [HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression](#).

Our fellows are preparing and submitting additional manuscripts that have been accepted for publishing related to the MAST Trial.

Dr. Punnen and team have enrolled 289 prostate biopsy patients to observe in the Marker Driven Selection of Patients for Prostate Biopsy and Management (MDSelect) trial. The study will help

determine if the interpretation of multiparametric MRI (mpMRI) with habitat risk score (HRS) algorithm in combination with a panel of blood and urine biomarkers is more effective at detecting prostate cancer than standard-of-care interpretation of mpMRI with the Prostate Imaging Reporting and Data System (PIRADS).

The American Urological Association (AUA) Southeast Section and AUA accepted DSUI-submitted abstracts on both MAST and MDSelect.

"As part of AUA's Clinical Trial Collective, I am working with academic, community and industry leaders to help our national association improve accrual to clinical trials and enhance clinical trial awareness around the nation. We are sharing the success DSUI has achieved in the clinical trials arena." Sanoj Punnen, M.D., M.A.S., M.B.A., professor of urology and vice chair of research.

Dr. Punnen is co-leading an NCI-funded project to develop a new, urine-based test for improved prostate cancer detection. This project is an ongoing collaboration with Exosome Diagnostics and utilizes urine samples from multiple clinical trials (MAST, MDSelect, ExoDx Active Surveillance, and biobank samples).

Erectile Function Post Prostatectomy

Dr. Punnen is also conducting the Phase 2 Randomized Trial: Human Amnion Membrane Allograft and Early Return of Erectile Function after Radical Prostatectomy (HAMMER). HAMMER researchers are evaluating whether placement of a dehydrated human amnion chorion membrane (dHACM) over nerves after prostate removal during radical prostatectomy will result in earlier post-surgical recovery of erectile function and urinary control.

Nonmuscle Invasive Bladder Cancer Database

Chad R. Ritch, M.D., M.B.A., FACS, DSUI professor of urologic oncology, has created a DSUI institutional nonmuscle invasive bladder cancer database. This large repository for analysis has yielded three published papers this year, looking at how we manage high-grade tumors and the impact of things like body mass index and metabolic syndrome on these patients' outcomes.

DSUI is a tertiary referral center for these complicated, non-muscle invasive bladder cancers, which makes this data a valuable resource for not only improving our outcomes but for sharing our research and trends with residents and others with questions about this cancer type.

Dr. Ritch and his team are analyzing results of a cohort from the same institutional database of high-risk bladder cancer patients, which they used to study an extensive panel of genomic markers. They analyzed the data to genomic clues to patient treatment response. They expect to soon publish results from that study.

Using AR to Improve Patient Education

Archan Khandekar, M.D., assistant professor of urologic oncology, designed the study, Evaluating Patient Perception and Decision-

Making through Augmented Reality Visualization of Abdominal Imaging Findings Using the Medivis Device with Microsoft HoloLens. The study's primary objective is to assess the impact of viewing abdominal imaging scans in a three-dimensional augmented reality (AR) environment on patient perception and understanding. The secondary objective is to evaluate the feasibility and patient acceptance of using the Medivis device with Microsoft HoloLens. Findings were presented at AUA, and this protocol will be expanded to include prostate MRI and kidney stone images.



GROWTH IN BASIC AND TRANSLATIONAL RESEARCH

Led by DSUI's Scientific Director Nima Sharifi, M.D., the Sharifi Lab has grown from a staff of 17 in 2023, when Dr. Sharifi first joined DSUI, to 23 [team members](#) today.

Researchers who have joined the Sharifi Lab this past year include:

- **Felipe Cassaro Vechin**, a visiting research scholar with a Ph.D. in exercise science. Dr. Vechin will be developing projects assessing the role of physical exercise on health outcomes in prostate cancer patients.
- **Kristina Shi**, a senior research associate with an M.S. in chemical engineering from Columbia University. Kristina will be assisting the Sharifi Lab in developing novel mass spectrometry techniques for the analysis of small molecules.

Zhipeng Wang, Ph.D., assistant professor of urology, has quickly expanded his laboratory since joining DSUI in June 2024. In a short time, Dr. Wang has assembled a productive research team, including Associate Scientist Ling Zhang, Ph.D., and Postdoctoral Associate Yuanfei Zhou, Ph.D. Together, they are driving forward discoveries related to how metabolite-driven, posttranslational modifications (PTMs) influence cancer. While

working in Miami, Dr. Wang has already uncovered unexpected pathways through which intermediate metabolites regulate PTMs and impact protein function, providing new insights into cancer biology.

"Our strength as a research Institute stems from DSUI's high level of integration between folks who do clinical urology and clinical research collaborating so closely with basic and translational research. This might sound intuitive, but to make it a reality like we have at DSUI is unusual. Many academic centers are structured so that those who do basic science, looking at mechanisms of cancer or mechanisms of disease, work separately from those who do clinical work or clinical research. We truly have it all under a single umbrella, with the same mandate, with the same direction. It's integrated so we can study things comprehensively from soup to nuts—from how things work at a very essential, basic level all the way to how it behaves in human disease. That's whether it has to do with cancer or other aspects that may be relevant to urology." Scientific Director Nima Sharifi, M.D.

Diet and Prostate Cancer

The DSUI Science team with Dr. Sanoj Punnen recently started a clinical study funded by the [Prostate Cancer Foundation](#) looking at the importance of diet in prostate cancer. Population level data suggests that diet is important for prostate cancer risk and clinical outcomes. But we do not yet understand how the components of what we eat influence prostate cancer development.



This multifaceted research of systemic biomarkers associated with the Mediterranean diet will provide in-depth understanding of the metabolic and systemic signatures of prostate tissue before and after dietary intervention. Results will provide a critical foundation for testing dietary interventions to learn whether such interventions can mitigate metabolic aberrations and improve patient quality of life.

Metabolism, Genetics, Biomarkers and Prostate Cancer

Dr. Sharifi's ongoing work at DSUI on metabolism and genetics also ties into biomarkers and development of new therapies—new drugs for prostate cancer. To help further research, Dr. Sharifi and colleagues are harnessing the power of innovation, including a technology that

looks at not only the total concentration of metabolites but also imaging metabolites. The goal is to get special resolution of various metabolites—whether nutritional components or other things that are made by the tumor—and apply that to surgical pathology. Use of this leading-edge imaging technology could help identify biologic drivers in prostate, kidney and bladder cancers.



Our strength as a research Institute stems from DSUI's high level of integration between folks who do clinical urology and clinical research collaborating so closely with basic and translational research.

Nima Sharifi, M.D., DSUI's Scientific Director

Dr. Sharifi's Work on HSD3B1 Genotype Influential a Decade Later

Dr. Sharifi authored [an invited commentary in JAMA Network Open](#) related to the HSD3B1 genotype, an allele he helped discover more than 10 years ago. The new study demonstrates the foundation of Dr. Sharifi's early research showing how the variant works and suggests that men who inherit the variant tend to have worse prostate cancer outcomes.

An additional clinical study published this past year in [The Journal of Clinical Investigation](#), together with a group of prostate cancer investigators in Australia and New Zealand, confirms that HSD3B1 is a key germline genetic biomarker, affecting clinical outcomes and response to treatment in patients with prostate cancer.

"This is a large, ethnically diverse study of prostate cancer patients. Now we can say with much greater confidence that this finding is clinically meaningful, as HSD3B1 status can inform prognosis and response to hormone therapy. Indeed, HSD3B1 appears to be the most common monogenic driver of prostate cancer mortality." Scientific Director Nima Sharifi, M.D.

Microplastics and Women's Reproductive Health

Raveen Syan, M.D., associate professor of clinical urology, and Ashutosh Agarwal, Ph.D., DSUI director of engineering and applied physics, are collaborating on the

study, Microplastics and Women's Health: Detection and Implications in Reproductive Tissue. Their objective is to determine presence of circulating and tissue-embedded microplastics in benign tissue samples of endometrium and myometrium from women undergoing hysterectomy. The researchers conducted pilot tests with tissue samples from the biobank to refine lab techniques for microplastic detection and analysis. Based on encouraging preliminary results, they plan

to scale up to continue the tissue collection, include blood and urine samples and request cancer center approvals to expand the collection to tumor tissue from gynecologic malignancies. In an [Inside U Medicine podcast](#), Dr. Syan said this first study to look at microplastics in tumor tissue in humans will help us better understand the tissues store that these particles and corresponding concentrations.

Female Urology Publications

Dr. Syan and colleagues all have published a collection of papers this fiscal year, looking at urinary incontinence to pelvic floor disorders, including:

Egemba, C, Duncan E, Amin K, Wein A, Caban-Martinez AJ, Syan R. Disparities in surgical treatments for stress, urge and mixed urinary incontinence: Evidence from the 2019 National Ambulatory Surgery Sample (NASS). *Continence* 2025, Vol 13. <https://www.sciencedirect.com/science/article/pii/S2772973725000050#:~:text=Results%3A,did%20not%20undergo%20surgical%20treatment>.

Venigalla G, Narasimman M, Satish S, Wein A, Amin KA, Syan R. Evaluating Pelvic Floor Disorder Care Among Racially Minoritized Women: A Focus Group Analysis. *Urology* 2025 Feb 10:S0090-4295(25)00138-4. PMID: 39938599 <https://pubmed.ncbi.nlm.nih.gov/39938599/>

Mohamud H, Sinclair S, Gunamany S, Burton CS, Zhang CA, Syan R, Enemchukwu EA. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines and Therapy Utilization Patterns. *Neurourology and Urodynamics* 2024 Nov 19. PMID: 39558806 <https://pubmed.ncbi.nlm.nih.gov/39558806/>

Rao HC, Meyer ML, Kominiarek MA, Daviglius ML, Gallo LC, Cordero C, Syan R, Perreira KM, Talavera GA, Fernández-Rhodes L. Polycystic Ovary Syndrome, Metabolic Syndrome, and Inflammation in the Hispanic Community Health Study/Study of Latinos. *J Clin Endocrinol Metab*. 2024 Jun 18:dgae426. doi: 10.1210/clinem/dgae426. Epub ahead of print. PMID: 38888178. <https://pubmed.ncbi.nlm.nih.gov/38888178/>

McHugh EG, Hinkes S, Chisolm A, Nguyen TV, Wein A, Amin K, Williams A, Syan R. Minority Women Undergo Surgical Treatment of Pelvic Organ Prolapse at Similar Rates to Non-minorities in a Hispanic Minority-majority Population: An Analysis of Nearly 1000 Women. *Urology*. 2024. PMID: 39173930. <https://pubmed.ncbi.nlm.nih.gov/39173930/>



Funding for a Pelvic Health Program for Cancer Survivors

Dr. Syan received intramural funding via the DSUI Genitourinary Research Development Pilot Grant Award 2024 to create a women's pelvic health program to assess and treat pelvic floor disorders during and after bladder cancer treatment. The ongoing research program looks at whether enrollment in a program with specialized care focusing on pelvic health can improve functional outcomes.

Botox for Pelvic Floor Hypertonicity?

Illustrating DSUI's collaborative, multidisciplinary research environment, Yingchun Zhang, Ph.D., professor of biomedical engineering at DSUI, was awarded an NIH grant to conduct the study, Assessing the Effects of Guided Precision Botulinum Neurotoxin Injections on Pelvic Floor High-Density Surface Electromyography. The study will look at the impact of precise, targeted injections of botulinum neurotoxin (commonly known as Botox) on pelvic floor hypertonicity and pain.

Drug-coated Balloon Treatment for Urethral Stenosis

Laura Horodyski, M.D., assistant professor of urology, and Ramgopal Satyanarayana, M.D., professor of urology, are collaborating on the study, Retrospective Review of Patients with Prior Pelvic Radiation Undergoing Drug-Coated Balloon Dilation (Optilume) for Treatment of Urethral Stricture. The purpose is to evaluate the safety and efficacy of using this drug-coated balloon urethral dilation in patients with posterior urethral stenosis who have a history of prior pelvic radiation therapy.



Collagenase Clostridium Histolyticum for Peyronie's Disease

Bruce Kava, M.D., professor of clinical urology and director of men's health, participated in the recently completed multicenter retrospective trial sponsored by Endo USA, A Noninterventional, RETROspective Multicenter Study to Evaluate the Effectiveness and Safety of XIAFLEX in Adult Male Participants with Ventral Curvature

of the Penis due to Peyronie's Disease (Retro-VC). This phase 4 study reviewed medical records to evaluate the safety and effectiveness of collagenase clostridium histolyticum (CCH) in the treatment of patients with Peyronie's disease and ventral penile curvature.

"As part of this multicenter collaboration with major U.S. centers, DSUI has performed more collagenase clostridium histolyticum injections than participating centers and

we have contributed more procedures and more patients to the cumulative database. As a result, DSUI was recognized in several abstracts on this work at the AUA and will present data at the Sexual Medicine Society of North America meeting in October 2025. DSUI is becoming a center of excellence in caring for patients with Peyronie's disease." Bruce Kava, M.D., professor of clinical urology and director of men's health

Testicular Function, Obesity and Secondary Hypogonadism

Rodrigo Lessi Pagani, M.D., assistant professor of urology, has been selected as site investigator for the international, multicenter trial, A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Response Trial Evaluating the Efficacy and Safety of Leflutroazole on Testicular Function in Men with Hypogonadotropic Hypogonadism. Emad Ibrahim, M.D., HCLD, associate professor of urology and neurological surgery and director of the Clinical Andrology Laboratory, was also selected to serve as one of the central labs conducting semen analysis for this study.

Sharing Our Experience with AI/AR

While last year's report focused on our plans to incorporate artificial intelligence and augmented reality, this year's edition centers on the progress we've made and the next steps for embedding these technologies into our clinical practice. We are also moving towards connecting the dots so far as patient outcomes are concerned and trying to develop home-grown solutions to evaluate them and attest them with the latest technology. Tools to decrease physician burden by automating operative notes are also in the beta stage.

The real story isn't about the technology itself. It's about connecting these innovations to meaningful improvements in patient health and giving our clinicians more time to do what they do best: care for people.

"AI is not the future. It is the present. At DSUI, we're transforming health care today through innovative applications of artificial intelligence and augmented reality.

Our AI systems are revolutionizing surgical evaluation, creating clinically meaningful metrics while actively combating physician burnout. Meanwhile, our AR technology is striving for improved precision in prostate biopsies and enables direct visualization of the kidney in the clinic, empowering physicians to help patients better understand their anatomy and conditions.

The impact extends beyond improved clinical outcomes. By streamlining workflows and enhancing communication, these technologies are rekindling physician satisfaction and reshaping what it means to practice medicine in the digital age." Dipen J. Parekh, M.D., DSUI's founding director and chief executive officer at UHealth—the University of Miami Health System.

REAL-WORLD APPLICATIONS

Assistant Professor Archan Khandekar, M.D., a former urology fellow at DSUI, is helping to spearhead AI and AR projects.

Enhanced Surgical Analysis with AI

DSUI partnered with a computer vision analysis company to implement AI technology that reviews surgical videos, as well as helps to analyze and optimize surgical procedures. DSUI uses the surgical AI platform routinely to capture, analyze and securely store procedure videos.

The next step is to leverage AI-powered computer vision models to automatically generate operative notes from surgical video data and integrate this documentation

directly into the clinical workflow, streamlining surgeon workload and improving data consistency.

Computer Vision Projects Results

- In partial nephrectomy procedures, an AI system provided highly accurate measurements of warm ischemia times, with an average discrepancy of just 8.3 seconds compared to manual documentation, which had a greater deviation of more than two minutes. (Published: [Accuracy of warm ischemia time measurement using a surgical intelligence software in partial nephrectomies: A validation study - PMC.](#))
- A pilot quality improvement project assessed the necessity of routine postoperative labs in patients undergoing partial or radical nephrectomy. An AI model was used to predict which patients would exhibit clinically significant lab abnormalities, correctly identifying 70% of elevated creatinine cases and 60% with major hemoglobin drops. The long-term goal is to integrate these predictive insights with key clinical parameters and surgical video analysis, ultimately building a hybrid clinical-computer vision tool to guide individualized decisions on postoperative lab testing.

AI is not the future. It is the present. At DSUI, we're transforming health care today through innovative applications of artificial intelligence and augmented reality.

Dipen J. Parekh, M.D., DSUI's founding director and chief executive officer at UHealth—the University of Miami Health System



Advanced Surgical Documentation

- DSUI integrated Large Language Models (LLM) within its documentation system, reviewing 2,909 surgical events and significantly improving operative reporting accuracy. AI identified that 20.2% of events were missing and 1.2% inaccurately reported.
- The AI system effectively pinpointed clinically important omissions, reinforcing the necessity of precise documentation for patient safety, clinical operations and accurate billing.
- DSUI is using this model to create automated op notes that would reduce physician burnout in urology and beyond by streamlining the documentation process.

Natural Language Processing in Kidney Stone Analysis

- DSUI has implemented a sophisticated Natural Language Processing (NLP) system to automatically extract stone composition data from more than 3,000 reports. This system achieved perfect accuracy in a tested sample, vastly improving research efficiency and clinical management of kidney stones.

"Augmented reality is advancing precision in urologic oncology by transforming complex anatomy into an intuitive visual guide, helping surgeons operate with greater clarity and enabling patients to better understand their own anatomy and care." Archan Khandekar, M.D., assistant professor in urologic oncology.

Using a Microsoft Hololens with Medivis Software Integration for a "Clinic of the Future" Patient Engagement

- We conducted a prospective study using AR to help patients better understand renal mass imaging. The AR experience significantly boosted patient comprehension scores, from an average of 3.55 to 4.80 (on a 5-point scale), without increasing patient anxiety.
- Patient satisfaction was exceptionally high, with more than 94% of patients saying they would recommend AR experiences to others.

Advanced Prostate Biopsy Techniques

- We have begun to analyze an innovative, AR-guided biopsy method for prostate cancer diagnosis, directly comparing its effectiveness to traditional, micro-ultrasound techniques. [\(See more about this on our Clinical pages.\)](#)

Bruno Nahar, M.D., associate professor of urologic oncology and the Eric and Elizabeth Feder Family Endowed Chair in Urologic Oncology at the Miller School, is testing the use of AR headsets in the operating room to zero in on suspicious lesions during transperineal biopsy procedures.



We're uploading MRI and slide images to the headset, basically overlaying the images on the patient to see exactly where the lesion is. You can even measure the distance from the probe into the lesion by using the augmented reality, which can potentially help with targeting and making sure you're hitting the right spot on the prostate.

Bruno Nahar, M.D, associate professor of urologic oncology



Pathology and Active Surveillance

- We partnered with industry to create and validate AI-based algorithms on data from the MAST Trial Active Surveillance Data. (See more in our Research pages about the MAST trial.)

Multidisciplinary DSUI Lab to “Build” Ureteroscopy Surgical Assistant

“The Guided-Lithotripter with Diagnostic Endoscopic Robot (GLiDER) lab is a unique initiative—a multidisciplinary lab focused on automation and surgery as a collaboration between the departments of computer science and urology. We are developing surgical assistance for ureteroscopy with laser lithotripsy harnessing recent breakthroughs in computer vision and simulation and giving opportunities to college students, medical students, residents and graduate students to work together in this exciting space.” Endourologist Jonathan Elliott Katz, M.D., assistant professor of urology and GLiDER lab co-principal investigator.

The DSUI-funded GLiDER lab's first project is to build a surgical assistant for ureteroscopy with laser lithotripsy. The technology will work alongside human surgeons to do some of the procedure's tedious but highly important aspects, including lasering the stone into fine dust (where precision is key).

Dr. Katz and GLiDER co-principal investigator Ubbo Visser, Ph.D., M.S., associate professor of computer science at the University of Miami, are building an entire simulation of a robot with an off-the-shelf ureteroscope, resulting in digitally simulated software. The platform enables high-fidelity simulation with real physical properties, allowing for the application or reduction of gravity and accommodation for fluid dynamics.

Steps in the process include replicating the kidney, stone, laser, ureteroscope and robot

to take the project from a bench-top model to, one day, a surgical assistant in operations performed on humans.

While there are groups working on specific aspects, such as building robotic ureteroscopes, few, if any, have a multidisciplinary lab with this level of commitment and collaboration.

It's the reason, Dr. Katz, a former DSUI urology resident, returned to DSUI to join our faculty. “Dipen Parekh's vision and support in this area is why I came back.”



Meetings of the Minds

DSUI faculty embrace collaboration. We understand the importance of knowledge sharing and we provide several opportunities each year—from global meetings to retreats with our clinicians, scientists and trainees—for networking, collaboration and collective learning.

UROLOGY ON THE BEACH

The third annual “[Urology on the Beach](#)” conference in January 2025 at the Fontainebleau Miami Beach, had the largest attendance yet, attracting physicians, advanced practice providers, researchers, trainees and others from around the world. Dipen Parekh, M.D., founding director of DSUI and chief executive officer for UHealth—the University of Miami Health System, is the meeting's course director.

From 2024 to 2025, Urology on the Beach experienced growth in attendance, with many international attendees now flying in from countries such as Brazil, Canada, Colombia, Mexico and Israel.

Thought leaders shared the latest in urological research, clinical care and technologies. And many joined in conversations around the general theme of this report: innovation, including artificial

intelligence (AI) and augmented reality (AR). Moderating the meeting's Future of Technology discussion, Archan Khandekar, M.D., assistant professor of urologic oncology, orchestrated a discussion with several industry and scientific leaders.

“DSUI's annual three-day conference provides a platform where world-renowned experts from DSUI and academic centers and institutions globally present and discuss what they've experienced and studied. It's a place where anyone in the specialty can elevate their knowledge, regardless of their urologic subspecialty. We address all the timely topics—from urologic oncology to male health and pelvic floor dysfunction. Another thing that sets us apart is the meeting's intimacy and backdrop. Attendees and experts talk one-on-one in the beautiful, family getaway of Miami Beach.” Urology on the Beach Co-director Bruno Nahar, M.D., associate professor of urologic oncology and the Eric and Elizabeth Feder Family Endowed Chair in Urologic Oncology Research.



“Urology on the Beach offers trainees unprecedented experiences. Our Rising Star session provides a platform for residents from across the country to showcase their innovative research. Our Surgical and Innovation Theater is another opportunity for trainees to present their work. In another measure of success, we are enjoying increasing media exposure for Urology on the Beach, with prominent urological trade publications in attendance and widespread published articles extending our reach.” Urology on the Beach Co-director Raveen Syan, M.D., associate professor of clinical urology.

DSUI's annual three-day conference provides a platform where world-renowned experts from DSUI and academic centers and institutions globally present and discuss what they've experienced and studied. It's a place where anyone in the specialty can elevate their knowledge, regardless of their urologic subspecialty. We address all the timely topics—from urologic oncology to male health and pelvic floor dysfunction. Another thing that sets us apart is the meeting's intimacy and backdrop.

Bruno Nahar, M.D., Urology on the Beach Co-director



Urology on the Beach has emerged as a strategic platform for leading urological organizations to engage in meaningful knowledge exchange and professional development.

In 2025, DSUI leaders partnered with the Florida Urological Society to foster networking and collaboration within the Florida urology community, including a dedicated conference session at Urology on the Beach.

Another new session was moderated by the executive editor of AUA and the editor-in-chief of the *Journal of Urology*, offering valuable insights on how to successfully publish works and providing attendees with practical guidance on advancing their academic and professional impact.

KNOWLEDGE SHARING BEYOND THE CONFERENCE



University of Miami media channels are helping to spread the knowledge shared at events like Urology on the Beach. In an [Inside U Miami Medicine](#), Miller School Dean Henri R. Ford, M.D., M.H.A., and Dipen Parekh, M.D., founding director of DSUI and chief executive officer for UHealth—the University of Miami Health System, had an unscripted conversation about prostate cancer overtreatment with Ian Thompson, Jr., M.D., Urology on the Beach 2025 speaker and professor emeritus at the University of Texas Health Science Center San Antonio.

Dr. Thompson has spent his career studying this conundrum. During this episode, he discussed seminal findings in large-scale trials that showed invasive treatments are associated with substantial, potentially life-threatening conditions, including a three-fold risk of bladder cancer after radiation.

MIAMI SYMPOSIUM ON HUMAN METABOLISM 2025

In partnership with [Sylvester Comprehensive Cancer Center](#), DSUI hosted the second annual Miami Symposium on Human Metabolism in Miami Beach in February.

The Miami Symposium on Human Metabolism is an intimate, novel and fascinating opportunity that fosters new ways of thinking and perspectives on health and wellness.

"We explore essential mechanisms of human metabolism, trying to understand the mechanisms not just in model systems but in people, which is very challenging. To do this, we bring in speakers from around the world who have expertise in diet and longevity, metabolic aberrations and advanced metabolism imaging. Our speakers delve into new metabolite identification, including metabolites that mediate the interaction between diet and cancer risk or cancer outcomes, as well as those that come from exercise and metabolism that occurs in muscle." Symposium on Human Metabolism Director and DSUI Scientific Director Nima Sharifi, M.D.

The knowledge gained impacts urological patients, including disease process and treatment outcomes associated with such diseases as prostate cancer.



and studied in a modular fashion. These human-on-chip models are being deployed collaboratively in both academic labs for basic mechanistic studies, as well as in drug discovery efforts by pharmaceutical companies." Ashutosh Agarwal, Ph.D.

ANNUAL RESEARCH RETREAT: WHERE STUDIES ARE BORN



One of the most impactful things we do at DSUI is foster collaboration and communication inside the Institute during the Annual Research Retreat.

Among the takeaways from the more than 60 researchers and staff who attended last year's retreat was the need for more collaboration and integration of clinical and research teams at the Institute. As a result, in 2025, we began holding several smaller meetings throughout the year with our basic and translational research teams, clinicians and engineers, all aimed at providing forums for DSUI's multidisciplinary teams to share ideas and resources. In this end, the meetings pave the way for new studies.

This year's one-day symposium featured a range of topics, from how inherited genes may influence health or disease to how dietary interventions and other lifestyle factors can maintain a state of health and reduce disease risk. Experts addressed nutritional strategies to improve metabolic health and, potentially, longevity.



Ashutosh Agarwal, Ph.D., director of engineering and applied physics at Desai Sethi Urology Institute and associate professor of biomedical engineering at the University of Miami College of Engineering, presented Physiometric Microsystems for Studying Metabolism.

"I introduced the concept of two new species, *Homo Chippus* (milliscale version of a human) and *Homo Chippiens* (microscale version of a human) that we have been developing as improved models to study human metabolism. They offer several advantages over conventional cell culture and animal models. Human cells are cultured in biomimetic environments so they don't feel homesick, the signals are not diluted so they can be detected with high sensitivity and organ-organ interactions can be isolated

To incentivize research and collaboration, we continued the DSUI Pilot Grant program. We had more proposals, including collaborative proposals, in this second year of the program than the first. We are excited to announce that external and internal reviewers of those proposals have chosen these projects to receive funding:

Zhipeng Wang, Ph.D., assistant professor, was awarded for his study, "Ketogenic Diet Impact on Lysine β -Hydroxybutyloine in Prostate Cancer."

Katherine Amin, M.D., associate professor of urology, will receive funding for "PROtectS Trial: Prophylactic Polyacrylamide Hydrogel for de novo Stress Urinary Incontinence Prevention at Time of Prolapse Repair: A Pilot Study."

"The Annual Research Retreat gives voices to talented scientists with diverse backgrounds and disciplines, who might otherwise work in silos. It's amazing what we learn in these retreats, simply by getting everyone in the same room." DSUI Scientific Director Nima Sharifi, M.D.

2025 AUA Highlights



On the Podium

AUA selected Raveen Syan, M.D., associate professor of clinical urology, to give a podium presentation and feature her poster at the Research Forum: Early-Career Investigators Showcase at the 2025 Annual Meeting in Las Vegas.

Dr. Syan's research shows some women with pelvic floor disorders face challenges—such as limited information, difficulty navigating the health system and concerns about trust—that can affect their ability to access care. Dr. Syan and colleagues are evaluating if enrollment in a program with a urogynecology specialist improves pelvic floor disorder outcomes for female bladder cancer patients.

"This is quite an honor, as the list of prior invited presenters includes the best in the



In addition to our faculty and trainees speaking and presenting on a spectrum of timely urological topics during more than 25 sessions and panel discussions, DSUI celebrated milestones at [AUA 2025](#) that reflect our leadership in the specialty.

“This is quite an honor, as the list of prior invited presenters includes the best in the field. It is a privilege to contribute to the field of health disparities research, and I am grateful to be part of a community in Miami where I have the opportunity to improve treatment outcomes among all women.”

Raveen Syan, M.D., associate professor of clinical urology

field. It is a privilege to contribute to the field of health disparities research, and I am grateful to be part of a community in Miami where I have the opportunity to improve treatment outcomes among all women.”
Raveen Syan, M.D.

Chosen to Lead

Chad Ritch, M.D., M.B.A., was selected by the Southeastern Section to participate in the highly competitive and coveted [2025-2026 AUA Leadership Program](#), and he and other U.S. recipients were recognized during the Las Vegas meeting.

Dr. Ritch's selection, according to the AUA's acceptance letter, "... is a direct reflection of both your achievements and demonstrated leadership skills in the field of urology."

As a result, Dr. Ritch will participate in the AUA's in-depth leadership training, networking and mentoring opportunities.

"This is a steppingstone toward national leadership positions in AUA, and I look

forward to embracing this opportunity and making an impact on the future of our specialty." Chad Ritch, M.D., M.B.A., professor of urologic oncology.



Emphasis on Hands-on Education



Department of Urology Chair Mark Gonzalgo, M.D., Ph.D., M.B.A., who leads AUA's education initiatives as the organization's education chair, helps to ensure the quality and medical accuracy of educational content provided by the AUA at the annual meeting and beyond.

"We recognize that surgical proficiency can be enhanced through experience. That is why the AUA is committed to expanding learning opportunities—giving urologists, APPs and trainees the opportunity to engage directly with techniques they will use in practice. Hands-on courses go beyond theory to provide practical training that elevates clinical excellence." Department of Urology Chair Mark Gonzalgo, M.D., Ph.D., M.B.A.

Sharing DSUI's Clinical Trial Success on National Podium

As part of his leadership responsibilities with the AUA's [Clinical Trials](#) Collective, Sanoj Punnen, M.D., professor of urology and vice chair of research, has shared DSUI's success in developing a robust clinical trial portfolio on the national stage.



The AUA has a similar goal to increase clinical trial accrual in the specialty by engaging industry and community partners, as well as improving clinical trial awareness nationally. Dr. Punnen is among the academic and community leaders helping to design a plan for the AUA. At the annual meeting, Dr. Punnen was part of the Collaboration of Three Worlds – Independent Practice, Academia, and Pharma panel discussion.

"At DSUI, we have successfully invested in building a robust clinical trial portfolio. These forums at the AUA are great platforms for us to share our experiences with others, so we can gain from each other's expertise and challenges and do a better job facilitating clinical trials access and research to our patients throughout the nation." Sanoj Punnen, M.D., M.A.S., M.B.A.



Pioneering Improvements in LUTS Management

With more than six decades experience as a urologist, academician, researcher and revered mentor, Alan J. Wein, M.D., Ph.D. (hon), FACS, professor of clinical urology director of business development and mentoring, has much to share. During a Geriatric Urological Society session at the AUA 2024 annual meeting, Dr. Wein [discussed](#) how aging impacts lower-urinary tract symptoms (LUTS). He addressed important findings and much-needed areas of study, including his ongoing work on the role of oxidative stress in LUTS.

"Furthering our knowledge about LUTS had been overlooked, but today the treatment and investigational pipelines are full of options that promise to improve these patients' quality of life. Doctors might never know their patients are suffering if they don't ask the simple question, 'Do you ever leak any urine?'" Alan J. Wein, M.D., Ph.D. (hon), FACS.

Education

SHAPING TOMORROW'S UROLOGY LEADERS, INNOVATORS

DSUI faculty provide a learning environment that exposes medical students, fellows and residents to diverse practice types, from one-on-one clinical care to the dynamic and demanding nature of the tertiary care setting.

DSUI faculty embrace diverse opportunities for educating and mentoring future urologists and urology researchers in a personalized, attentive environment.

This year's chief residents reflected on the strength of their training, highlighting exposure to dynamic clinical environments, exceptional mentorship and a collaborative culture that strengthened their surgical skills, adaptability and professional growth.

"We encourage all of our trainees follow their career goals and pursue innovation. That's why so many of them (including all the residents from our class of 2022) have returned to join our faculty." Robert Marcovich, M.D., associate professor of urology and urology residency program director.

Taking the Pulse of the DSUI Residency Experience

It's one thing to believe our educational program is exceptional. It's another to hear it from our graduating chief residents.

This year's chief residents reflected on the strength of their training, highlighting exposure to dynamic clinical environments, exceptional mentorship and a collaborative culture that strengthened their surgical skills, adaptability and professional growth.

"Rotating through UHealth, Jackson Memorial Hospital and the VA, I gained expertise in high-volume surgical efficiency, adaptability in resource-limited environments and complex clinical and surgical management. I honed advanced surgical techniques, from robotic and endourologic procedures to intricate reconstructive cases. With

dedicated mentors always available, I refined my clinical judgment, leadership skills and patient-centered approach. This comprehensive training has equipped me with the confidence, skillset and resilience to excel in my career and tackle the evolving challenges of urologic practice, regardless of what lies on the road ahead," said Vinayak Madhusoodanan, M.D., who is pursuing a fellowship at Baylor College of Medicine in Houston, Texas.

"The diversity of training environments strengthened my clinical judgment, broadened my surgical skill set and deepened my understanding of healthcare delivery. As Chief Resident, I had the privilege of mentoring junior colleagues while refining my leadership abilities. Looking back, I am profoundly grateful for the challenges, mentorship and relationships that have defined this journey and prepared me for the next chapter of my career," said Joshua Bitran, M.D., who will be joining Mount Sinai in Miami Beach, Florida.

"The mentorship I have received has been invaluable, offering guidance, encouragement and opportunities to refine my skills in a supportive and collaborative environment. My training has provided me with a rich and varied surgical experience, where I now feel confident embarking on my career as a general urologist who can



provide excellent patient care. Throughout my training, teamwork has been at the heart of every success, as I've worked closely with fellow residents, attending surgeons, nurses and other healthcare professionals to ensure the best outcomes for our patients. Working in downtown Miami has not only broadened my perspectives but also reinforced the importance of inclusive care that respects each patient's unique background. Residency has solidified my passion for urology and strengthened my commitment to lifelong learning, mentorship and working collaboratively to provide exceptional care," said Maxwell Towe, M.D., who will be joining AdventHealth, Orlando, Florida.

Giving Residents the Spotlight

We emphasize the importance of research and innovation at DSUI and encourage residents to take part in the clinical trials and studies taking place at the Institute and/or in collaboration with others in urologic academic medicine.

As a result, these DSUI residents presented their work at major medical meetings throughout the year.

Jamie Thomas, D.O., presented "[Validation of PAM50 for predicting progression in active surveillance: Results from the Miami MAST prospective clinical trial](#)" in March at the Southeast Section of the AUA (SESAUA) meeting. Mentor Sanoj Punnen, M.D.



Jordan Best, M.D., presented "[A case of glans necrosis status post placement of an inflatable penile implantation in a 35-yo patient with type I muscular dystrophy](#)" in October at the Sexual Medicine Society of North America (SMSNA) meeting. Mentor Laura Horodyski, M.D.

Dr. Best also presented "[Snip, Support, and Shared Stories: Exploring Reddit Users' Experiences with Vasectomy](#)" at SMSNA. Mentor Thomas Masterson, M.D.

At the Florida Urologic Society in December, Dr. Best presented "Case of an iliac artery pseudoaneurysm with a ureteroiliac fistula." Mentor Robert Marcovich, M.D.

Ashley Gordon, M.D., presented "[Simulated Kidney and Kidney Stone to Evaluate Optimal Positioning for Ureteroscopy](#)" at SESAUA and at AUA. Mentor Jonathan Katz, M.D.

Joshua Mondshine, M.D., presented "Kidney stones/AI: using large language learning model to extract unstructured EHR data on stone composition," at AUA. Mentor Hemendra Shah, M.D.

Welcoming Incoming DSUI Residents 2025

We are pleased to introduce the incoming class of urology residents. Their varied backgrounds, strong academic foundations and commitment to clinical excellence align with DSUI's mission to train future leaders in urologic care. We look forward to growing together.



Umberto Donato, M.D.,
University of South
Florida (USF) Health
Morsani College of
Medicine



Etienne Gonzlan, M.D.,
University of Miami Miller
School of Medicine



Hunter Hernandez, M.D.,
New York University
Grossman School of
Medicine



Kyle Moore, M.D.,
Rutgers, Robert Wood
Johnson Medical School

DSUI FELLOWSHIP NEWS

Fellowship in Men's Health, Sexual and Reproductive Medicine, and Andrology Earns Accreditation

The Sexual Medicine Society of North America (SMSNA) has accredited DSUI's Fellowship in [Men's Health, Sexual and Reproductive Medicine, and Andrology](#). Designated a "select" program due to its inclusiveness and desirability in the specialty, the one-year fellowship is accepting applications for one fellow annually.

This is an opportunity for exceptional, hands-on training in urologic prosthetics (penile implants and artificial urinary sphincters), Peyronie's disease (plaque incision and grafting, plication procedures and prosthetics), microscopic surgery (varicocelectomy, vasovasostomy and vasoepididymostomy), office procedures (vasectomy, testosterone pellet implantation, intralesional Peyronie's plaque injections and penile Doppler ultrasonography), urethroplasty and minimally invasive BPH procedures (Aquablation, water vapor thermotherapy, Holmium laser enucleation and TURP).

"This fellowship is unique in that it also combines reproductive medicine and reconstructive medicine. It's part of our focus to move the men's health platform to more of mainstream urology and other specialty practices, including benign prostate disorders, as well as reproductive medicine, fertility and reconstruction (particularly male urethral reconstruction)." Bruce Kava, M.D., professor of clinical urology and director of men's health at the University of Miami Miller School of Medicine.

Urogynecology and Reconstructive Pelvic Surgery Fellowship Update

A urologist and gynecologist were the first fellows in August 2024 to participate in DSUI's Urogynecology and Reconstructive Pelvic Surgery (URPS) fellowship. In this year, DSUI's American College of Graduate Medical Education (ACGME)-approved fellowship came through the six-month ACGME site visit with flying colors.

"This fellowship brings national recognition to DSUI, as we are the only URPS fellowship in South Florida and one of less than a dozen ACGME-accredited dual urology/urogynecology fellowships nationally. Trainees will sit for board certification after they have completed their training." Katherine Amin, M.D., associate professor of clinical urology and program director, Urogynecology and Reconstructive Pelvic Surgery (URPS) fellowship.

Educating Community Urology Providers

DSUI has long been at the forefront of treating men's health issues, for which urologists are the primary care providers in the U.S.

Bruce Kava, M.D., professor of clinical urology and director of men's health at DSUI, as well as the current president of the [American Society for Men's Health](#), helped to spearhead the [Men's Health Boot Camp](#) at DSUI. The bootcamp is designed to provide a hands-on, one-on-one educational experience for providers from around the U.S., including urologists, physician assistants and extenders to medical students. Those who attend learn how to perform the latest treatments for men with erectile dysfunction, Peyronie's disease and testosterone deficiency, with an additional focus on how to provide preventive medicine strategies aimed at preserving men's long-term health.

"We established the bootcamp with a grant from industry and have trained 24 providers in the immersive experience. Providers learn how to optimally perform collagenase injections for patients with Peyronie's disease, testosterone pellet insertion and penile doppler ultrasonography (which is critical for the management of sexual disorders), as well as manage complicated patients in men's health—those patients with BPH, hypogonadism and sexual disorders. Feedback has been overwhelmingly positive." Bruce Kava, M.D., professor of clinical urology and director of men's health.

Grand Rounds Officially Launched



GRAND ROUNDS

DSUI successfully launched its CME-accredited Grand Rounds series—open to all urologists, regardless of affiliation. Led by Raveen Syan, M.D., associate professor of clinical urology, each session is organized around monthly themes such as bladder cancer, prostate cancer, pelvic reconstruction and other key topics. Esteemed DSUI faculty and nationally recognized leaders deliver presentations aimed at sharing the latest innovations in urology, updating clinical management approaches and, most importantly, strengthening connections with urologists nationwide to build a more integrated and collaborative network.

DSUI Hosts International Observers

DSUI invited 11 international observers from the William J. Harrington Programs, which are housed within the International Medicine Institute, the international component of

University of Miami Health System and the Miller School of Medicine.

The program provides state-of-the-art medical education to students and physicians from Latin American countries: Mexico, Central and South America and the Caribbean. Selected physicians and students receive training at the Miller School and return home to influence their medical communities through education and leadership.

This fiscal year alone, DSUI helped to train 11 people in the William J. Harrington Medical Student Program, a three-to-six-month experience during which observers attend morning rounds, clinics, case presentations, lectures and seminars, as

well as the program's Elective Program for Medical Graduates, which offers physicians individualized options for one and three months of an advanced educational experience at DSUI.

DSUI Visiting Professors

DSUI welcomes an impressive roster of visiting professors each year. These esteemed colleagues lend their perspectives, experience and knowledge about relevant and timely topics, from how best to care for urologic diseases to how to harness the power of innovation, including AI.

This aligns with the Institute's commitment to providing exceptional educational experiences for our trainees—the future of our profession.



Meet Our Visiting Professors in 2024-2025.

MARSHALL L. STOLLER, M.D. Endourology



Professor and Vice Chair of Urology, University of California, San Francisco
Topic: Increase the Joy for Life through Collaborations

ARMANDO LORENZO, M.D., MSC, FRCFC, FAAP, FACS Pediatric Oncology



Professor and Division Head, Pediatric Urology, SickKids Hospital, Toronto, Canada
Topic: AI in Urology: Challenges and Opportunities

GARY E. LEMACK, M.D. URPS



Professor of Urology and Neurology, Rose Mary Haggart Professor of Urology, UT Southwestern Medical Center.

Topic: Are Urodynamics Still Relevant in the

Evaluation of Men with LUTS in 2025?
How to Decrease the Risk of Patient Disappointment Following Benign Prostate Surgery.

3rd Annual Maria Becerra Visiting Professor: ROBERT UZZO, M.D., M.B.A., FACS Urologic Oncology



President and CEO, Fox Chase Cancer Center

Topic: The Evolving Resident Surgical Experience: Are Urology Trainees Prepared for

Independent Practice in 2025?

Renal Cell Carcinoma: In the Beginning



DSUI's Maria Becerra Visiting Professor Designation

Maria F. Becerra, M.D., was a DSUI urology resident who passed away in 2022.

After graduating medical school in her native Colombia, Dr. Becerra took a position as a research associate in urologic oncology at Memorial Sloan Kettering Cancer Center in New York. Her mentor there was Joel Sheinfeld, M.D., one of the most influential contemporary urologic oncologists.

Dr. Becerra matched into our urology residency program in 2017.

Near the end of her PGY1 year she was diagnosed with a very serious medical condition, which tragically became terminal, despite her valiant and prolonged struggle.

We will not forget Dr. Becerra's passion for genitourinary oncology. An accomplished physician in her short time on earth, Dr. Becerra co-authored 30 peer-reviewed articles. Residents remembered her for advocating for their well-being and pushing for improvements to the residency program. She initiated post-call day off and our current night float call system.

Dr. Becerra was a role model and the Institute thought it fitting to name the visiting professor for oncology after her legacy.

Scrub Tech Patricia Adams Honored with the Jackie Meneses Urology MVP Award



Jackson Memorial Hospital Scrub Tech Patricia Adams is the 2025 recipient of the Jacqueline Meneses Urology MVP Award, an honor selected by DSUI chief residents.

Patricia was selected for her dedication to excellence and, above all, for her unwavering support and care.

The award is named after Jacqueline Meneses, a former DSUI program residency manager. She passed away in 2023 after being a part of the Department of Urology for more than 20 years.

Residents from as recently as the class of 2022 remembered the power of Jackie's smile and her willingness to be a "stand-in mom."

Jackie made residency much more manageable and will be forever remembered with deep gratitude and affection, remarked one resident.

Chief Residents Select Dr. Nahar

Our chief residents have spoken. This year's Faculty Teaching Award goes to Bruno Nahar, M.D., associate professor of urologic oncology and the Eric and Elizabeth Feder Family Endowed Chair in Urologic Oncology Research at the Miller School.



DESAI SETHI UROLOGY INSTITUTE (DSUI)

Administrative Happenings

BUILDING RELATIONSHIPS

AUA 2025 Networking



DSUI hosted its third annual AUA networking event in Las Vegas this year, continuing a highly anticipated tradition during the world's foremost meeting of urologists. Held at the Venetian Hotel, the event brought together DSUI faculty, trainees and alumni with urology teams from across the country in a relaxed and welcoming setting. Designed

to foster meaningful connections beyond the conference halls, the evening offered an invaluable opportunity to exchange ideas, share experiences and strengthen professional relationships.

Team Building Initiatives



DSUI's team recently enjoyed a happy hour to celebrate their consistent, month-over-month nursing performance exceeding the national benchmark, as reflected in patient satisfaction surveys. These surveys included questions about patients' experiences, such as staff friendliness and courtesy, respect for privacy and safety measures—areas in which the team excelled.

Pickleball Meetup



Pickleball is taking the DSUI faculty and staff by storm. Department of Urology Chair Mark Gonzalgo, M.D., Ph.D., M.B.A., kicked off DSUI's first-ever pickleball meet-up, a fun and active way to connect outside the clinic. With more events like this on the horizon, DSUI continues to foster wellness, relieve stress and strengthen team bonds through shared experiences.

I ride because living with cancer requires steady perseverance and endurance; similar to riding a bike. Cycling reflects the consistent effort needed to move forward, mile after mile, despite challenges along the way. Each ride reminds me of the quiet strength patients show daily, motivating me to keep going and support their journey.

Archan Khandekar, M.D., assistant professor in urologic oncology, who completed the 39-mile DCC cycling event

DSUI Goes All in for Dolphins Cancer Challenge

In the 15 years since it launched, the Dolphins Cancer Challenge (DCC) has grown from 400 to more than 7,300 participants and has raised more than \$15 million to support cancer research at Sylvester Comprehensive Cancer Center.

DSUI supports this great cause and in this fiscal year, our team had 24 members.

- **4 did the 39-mile bike ride**
- **1 did the 13-mile bike ride**
- **13 ran or walked the 5K**
- **DSUI raised more than \$18,500, far surpassing its \$10,000 goal.**

DSUI Hosts Inaugural Board Meeting



DSUI held its inaugural board meeting, marking an important milestone in our continued growth. The meeting brought together leadership and board members to discuss the institute's mission and set ambitious goals for the future. With a shared commitment to advancing urologic care, education and research, the board will continue to meet quarterly to guide and support the institute's evolving vision. We look forward to what lies ahead with great optimism and purpose.

Philanthropy

RECOGNIZING THE GIFT OF GIVING

At DSUI, we conduct the clinical trials and studies that we believe will translate to life-changing care.

As clinicians, our faculty are on the frontlines, listening to patients and learning about their needs. As researchers, these same physicians and scientists conduct research in the lab with multidisciplinary teams and innovative technologies to solve those challenges and meet those needs in a transformational model that turns successful studies into clinical care improvements in record time.

The progress we seek in improving the health and lives of urology patients would not be possible without the generosity of donors, like these, who believe in our work.

Recognizing Dr. Parekh as Standout Surgeon, Leader

"Dr. Parekh is the most experienced robotic surgeon in urologic oncology in America. No one has successfully overcome the complicated surgical cases that he has,

and my case, which involved removing my cancerous prostate, is one example. What should have been a three- to four-hour operation turned into six hours. Due to a motorcycle accident when I was 18, my prostate got embedded in my bladder. Dr. Parekh had to not only undo it but also biopsy my bladder to determine whether it had become cancerous. Fortunately, it had not. Still, Dr. Parekh knew what to do, remained calm (because he has done so many complex operations), and, today, I am free of cancer and any side effects or complications of the surgery.



"Anyone who knows Dipen knows he is not just a great surgeon but also a great leader in urology. Given his background, the size of the Institute doesn't intimidate him. I've watched him lead, and he's excellent." Hugh Culverhouse Jr., who donated \$1.55 million to the Desai Sethi Urology Institute.

Advancing Research on Women's Urogynecologic Concerns

"I've always focused my philanthropy on improving the lives of women and girls. [That includes] supporting various aspects

of reproductive health care, including clinical access, research and multidisciplinary collaboration.

"I see supporting advances in urogynecology as an extension of that interest.

"That's why I was excited to learn about Dr. Syan and Dr. Amin and their interdisciplinary approach to urogynecology practice. I have become more aware recently of the extent to which women are suffering with specific complaints that could be helped through treatment by a urogynecologist, and Drs. Syan and Amin are advancing treatments and research in the area.

"Historically women have just dealt with bladder issues and problems related to pelvic dysfunction because of childbirth or the natural aging processes. I think there are countless women who could be helped now, and countless girls who will be needing services when they're older, so I see them on a continuum of improvements in urology and gynecology in a way that could help women lead happier and more comfortable lives." Philanthropist and DSUI donor Jill E. Braufman, of the Daniel L. Nir and Jill E. Braufman Family Foundation.

We are grateful to all our donors, from generous philanthropic partners to patients and families who give what they can. Together, they make DSUI's transformative and innovative care model possible. DSUI shares a heartfelt thank you with every supporter who helps advance our mission.

Historically women have just dealt with bladder issues and problems related to pelvic dysfunction because of childbirth or the natural aging processes. I think there are countless women who could be helped now, and countless girls who will be needing services when they're older, so I see them on a continuum of improvements in urology and gynecology in a way that could help women lead happier and more comfortable lives.

Jill E. Braufman, philanthropist and DSUI donor



Below, we proudly recognize several of our leading donors whose extraordinary generosity has had a profound impact on our work:

Bharat N. Desai and Neerja Sethi
Daniel and Brett C. Sundheim
Terry R. and Carla Taylor
Hugh F. and Eliza Perlmutter Culverhouse
Patrick and Fernanda Dovigi
Manny and Ana M. Kadre
Eric M. and Elizabeth V. Feder
Anonymous
James and Karina Rogers
Rick and Ashley Gerson
Robert W. and Veronique C. Pittman

Paul and Marie-France Bloch
Prashant Nagar
Saul Fox
Ricardo Puente Family Foundation, Inc.
Emil G. and Julie Michael
Jeffrey Sandelman
John J. Gray
Walid G. and Susie A. Wahab
Nita and Dr. Vinod Kumar
Jose M. Garcia and Leslie Lorenzo
Anonymous
Alexandre Cukier and Maria Varcui
Jess and Sheila Varughese
Jill Braufman and Daniel Nir
Marlene Perlmutter
Jeff and Ali Zalaznick

David and Barbara Zalaznick
Ryan and Heidi Orley
Sandeep and Jolly Somaiya
Rohan Oza and Shaheen Patel
Giorgio Perfetti
Basil K. and Jane T. Vasiliou
Wallace H. Coulter Foundation
John C. and Joanne L. Sumberg
Donald E. Mudd
Andrew H. Zaro and Lois Robbins
Jorge L. Padron and
Maria G. Rodriguez Padron
Charles R. and Lourdes Hauser
Simran Foundation
Healthnetwork Foundation

DSUI Faculty

EXECUTIVE LEADERSHIP

Dipen J. Parekh, M.D.



Founding Director,
Desai Sethi Urology
Institute
Professor, Department
of Urology
Director of Robotic
Surgery

The Victor A. Politano Endowed Chair in
Clinical Urology
Executive Vice President of
Health Affairs, University of Miami
Chief Executive Officer, University of
Miami Health System
University of Miami Miller School of
Medicine

CHAIR

Mark Gonzalgo, M.D., Ph.D., M.B.A.



Professor & Chair,
Department of Urology
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

Executive Director, Perioperative Surgical
Services, University of Miami Health
System

ONCOLOGY

Sanoj Punnen, M.D., MAS



Professor, Department
of Urology
Vice Chair of Research,
Desai Sethi Urology
Institute
Assistant Director
of Clinical Research,

Sylvester Comprehensive Cancer Center
Pap Corps Champions for Cancer
Research Endowed Chair in Solid Tumor
Research

University of Miami Miller School of
Medicine

Archan Khandekar, M.D.



Assistant Professor,
Department of Urology
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

Ali Mouzannar, M.D.



Assistant Professor,
Department of Urology
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

Bruno Nahar, M.D.



Associate Professor,
Department of Urology
Desai Sethi Urology
Institute
Eric and Elizabeth
Feder Endowed Chair
in Urologic Oncology

Research, University of Miami Miller
School of Medicine

Chad Ritch, M.D.



Professor, Department
of Urology
Associate Program
Director, SUO
Fellowship
Director, Urologic
Oncology Fellowship

Desai Sethi Urology Institute
Director of Urology, UHealth Tower
Associate Director, UHealth International
University of Miami Miller School of
Medicine

Sanjaya Swain, M.D.



Associate Professor,
Department of Urology
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

MEN'S HEALTH

Laura Horodyski, M.D.

Additional Sub-Specialty:
Reconstructive Urology



Assistant Professor,
Department of Urology
Residency Associate
Program Director
Desai Sethi Urology
Institute
University of Miami
Miller School of Medicine

Emad Ibrahim, M.D., HCLD



Associate Professor,
Department of Urology
Clinical Andrology Lab
Director
Desai Sethi Urology
Institute
University of Miami
Miller School of Medicine

Bruce Kava, M.D., MSCTI



Professor, Department
of Urology
Director of Men's Health
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

Thomas III Masterson, M.D.



Assistant Professor,
Department of Urology
Desai Sethi Urology
Institute
University of Miami
Miller School of
Medicine

FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY

Katherine Amin, M.D.



Associate Professor,
Department of Urology
Program Director,
Urogynecology/
Female Pelvic Medicine
& Reconstructive
Surgery (FPMRS)
Fellowship Program

Desai Sethi Urology Institute
University of Miami Miller School of
Medicine

Raveen Syan, M.D.



Associate Professor,
Department of Urology
Director of Female
Pelvic Medicine and
Reconstructive Surgery
Desai Sethi Urology
Institute

University of Miami Miller School of
Medicine

Alan J. Wein, M.D., Ph.D. (hon), FACS

Professor, Department of Urology
Director of Business Development and Mentoring
Desai Sethi Institute of Urology

University of Miami Miller School of Medicine
Emeritus Professor, Chief and Program Director of Urology
University of Pennsylvania

ENDOUROLOGY

Jonathan Katz, M.D.

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Robert Marcovich, M.D.

Associate Professor, Department of Urology
Urology Residency Program Director
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Hemendra Shah, M.D., M.Ch., D.N.B., M.R.C.S.

Professor, Department of Urology
Program Director, Endourology Fellowship
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

GENERAL UROLOGY

Richard Davi, M.D.

Assistant Professor, Department of Urology
Director of Urology Lennar Foundation Medical Center
Desai Sethi Urology Institute

University of Miami Miller School of Medicine

Manuel Molina, M.D.

UMMG Staff Physician, Department of Urology
Desai Sethi Urology Institute
University of Miami Health System

Rodrigo Pagani, M.D.

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Dani Papir, M.D., FACS

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

David Rodin, M.D.

UMMG Staff Physician, Department of Urology
Medical Director - UHealth West Palm Beach
Desai Sethi Urology Institute
University of Miami Health System

Carlos Santa Cruz, M.D.

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Ramgopal Satyanarayana, M.D.

Professor, Department of Urology
Desai Sethi Urology Institute
Director, JMH Urology
University of Miami Miller School of Medicine

RESEARCH FACULTY

Ashutosh Agarwal, Ph.D.

Research Focus:
Physio mimetic Microsystems Laboratory

Associate Professor, Department of Urology, Department of Biomedical Engineering
Director of Engineering and Applied Physics, Desai Sethi Urology Institute

Co-Director: Engineering Cancer Cures, Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine

Mohammad Alyamani, Ph.D.

Research Focus:
Molecular Mechanisms and Translational Oncology

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Su Liu, Ph.D.

Research Focus: Biomedical signal processing and computational analysis of neurophysiological biomarkers for neurological disorders and rehabilitative BCI applications

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Nima Sharifi, M.D.

Research Focus:
Molecular Mechanisms and Translational Oncology

Professor, Department of Urology
Scientific Director, Desai Sethi Urology Institute
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine

Ziqi Zhu, Ph.D.

Research Focus:
Molecular Mechanisms and Translational Oncology

Assistant Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Zhipeng Wang, Ph.D.

Research Focus:
Protein post-translational modifications in cancer and aging

Associate Professor, Department of Urology
Desai Sethi Urology Institute
University of Miami Miller School of Medicine

Yingchun Zhang, Ph.D.

Research Focus:
Precision Rehabilitation

Professor, Department of Urology, Department of Biomedical Engineering
Desai Sethi Urology Institute, University of Miami

Department of Neurological Surgery, University of Miami
Miami Project to Cure Paralysis, University of Miami
Director, Predictive Modeling and Functional Imaging (PreMI) Laboratory, University of Miami
Co-Director, Neurourology Laboratory at Michael E. DeBakey VA Medical Center (MEDVAMC)
University of Miami Miller School of Medicine

CLINICAL INSTRUCTORS

Pedro Freitas, M.D.

Clinical Instructor



Hossein Sharifi, M.D.

Clinical Instructor



RESIDENTS

Robert Marcovich, M.D.

Residency Program Director



Joshua Bitran
PGY 5-Chief

Vinayak Madhusoodanan
PGY 5-Chief

Maxwell Towe
PGY 5-Chief

Jordan Best
PGY 4

Jessica Delgado
PGY 4

Ashley Gordon
PGY 4

Paulo Marcelo Moscardi
PGY 3

Mary Rostom
PGY 3

Sabika Sadiq
PGY 3

Alexandra Dullea
PGY 2

Joshua Mondshine
PGY 2

Maria Camila Suarez Arbelaez
PGY 2

Olubusola Osunsanya
PGY 1

Joao Porto
PGY 1

Nachiketh Soodana Prakash
PGY 1

Jamie Thomas
PGY 1

FELLOWS

Luciana Lerendegui
Pediatric Urology-Y2

Alfonso Gudino Villarreal
Infertility I Andrology-Y1

Aravindh Rathinam
Endourology-Y1

Omri Falik Nativ Urologic Oncology-Y1

Gareth Reid Urologic Oncology-Y1

Ruomei (Amy) Wu Female Pelvic & Reconstructive Surgery-Y1

Tamar Yacoel Female Pelvic & Reconstructive Surgery-Y1

INCOMING FELLOWS AND CLINICAL INSTRUCTORS

Jacques Jeudy, M.D.
Men's Health Clinical Instructor

Tejas Mistry, M.D.
Oncology Clinical Instructor

Gurpremjit Singh, M.D.
Endourology Clinical Instructor

Heather Steckenrider, M.D.
SUO Fellow

Leadership	10
Administrative Staff	41
Clinical Faculty	23
APPs/PAs	10
Nurses	4
Medical Assistants	9
Patient Access	3
Inpatient Staff	2
Research Faculty and Staff	35
Fellowships	7
Residents	16
Clinical Instructors	3
DEPARTMENTAL TOTAL	164

Presentations

AACR

APR 2025

Abstract 5315: MAPPING TUMOR INFILTRATING LYMPHOCYTES IN WHOLE PROSTATECTOMY SPECIMENS TO VISUALIZE AND QUANTIFY THE IMMUNE MICROENVIRONMENT OF PROSTATE CANCER FREE

Yuwei Zhang; Rajarsi Gupta; Joel Saltz; Tahsin Kurc; Jakub Kaczmarzyk; Erich Bremer; Veronica Wallaengen; Amanda Galvez; Abigail Bartley; Leonard Salcedo; Alan Pollack; Sanoj Punnen; Oleksandr Kryvenko; Radka Stoyanova; Sandra M. Gaston

APR 2025

Abstract 1929: METABOLOMIC INSIGHTS INTO ANDROGEN DEPRIVATION THERAPY, AND SALIVA AS A NON-INVASIVE SURROGATE FOR SERUM TO ENABLE COMMUNITY-BASED BIOMARKER STUDIES

Alireza Abdshah; Mohammad Alyamani; Marijo Bilusic; Dipen J. Parekh; Benjamin Spieler; Rakesh Singal; Brandon A. Mahal; Erin Kobetz; Sanoj Punnen; Matthew C. Abramowitz; Jaime R. Merchan; Nima Sharifi

AUA

MAY 2025

PD11-06: EFFICACY AND SAFETY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT IN PATIENTS WITH COMPLEX PENILE PLAQUES

Pantoja GM, Saffati G, Hernandez BS, Hinojosa-Gonzalez DE, Williams AD, Kava B, et al.

MAY 2025

PD11-09: A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER TRIAL TO EVALUATE SAFETY AND EFFICACY OF PLATELET-RICH PLASMA INJECTIONS FOR PEYRONIE'S DISEASE: CLINICAL TRIAL UPDATE

Manuel Molina, Laura Angulo-Llanos, Kristin Perruci, Thomas Masterson, and Bruce Kava

MAY 2025

MP10-14: COMPARATIVE ANALYSIS OF TARGETED VS. SYSTEMATIC BIOPSY IN DETECTING GRADE PROGRESSION AMONG MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER

Seyed Hossein Hosseini Sharifi, Laura Angulo, Hui Yu, Joao Porto, Nachiketh Soodana Prakash, Archan Khandekar, Mikel Curet, Tarek Ajami, Elena Cortizas, Timothy Guerard, Zoe Szczotka, Sanjaya Swain, Oleksandr Kryvenko, Alan Dal Pra, Radka Stoyanova, Alan Pollack, Brandon Mahal, Matthew Abramowitz, Bruno Nahar, Chad Ryan Ritch, Bruce Kava, Mark A. Gonzalgo, Dipen J. Parekh, and Sanoj Punnen

MAY 2025

MP12-20: FAILURE RATES ASSOCIATED WITH UNCERTAIN VASECTOMY PATHOLOGY REPORTS

Max D. Sandler, Laura Angulo-Llanos, Rohan Dureja, Adriana Sandino, Faaris Khan, Veronica Junco, Dan V. Tran, Julio Yanes, and Thomas A. Masterson

MAY 2025

PD11-07: PEYRONIE' S DISEASE OUTCOMES FOLLOWING COLLAGENASE CLOSTRIDIUM HISTOLYTICUM MAY NOT DIFFER BY SEXUAL ORIENTATION

Jake A. Miller; Muhammed A. Hammad, Helen L. Bernie, Laura Angulo-Llanos, Timothy Guerard, Beatriz S. Hernandez, David E. Hinojosa-Gonzalez, Tung-Chin Hsieh, Bruce Kava, Mohit Khera, Thomas A. Masterson, Vi Nguyen, Geneva M. Pantoja, Thairo A. Pereira, Gal Saffati, and Faysal Ayafi

MAY 2025

PD03-06: BEYOND P-VALUES: APPLICATION OF FRAGILITY AND REVERSE FRAGILITY INDICES IN TRIALS FOR INTERSTITIAL CYSTITIS

Christina C. Yarborough, Jason M. Codrington, Alan J. Wein, Raveen Syan

MAY 2025

MP24-03: EXOGENOUS SYSTEMIC ESTROGEN USE BUT NOT HIGHER CONSUMPTION OF PHYTOESTROGEN-RICH FOOD IS ASSOCIATED WITH PELVIC FLOOR DISORDERS IN WOMEN: EVIDENCE FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES)

Edith Duncan, Christabel Egemba, Alan Wein, Raveen Syan, Adam Williams, Stacy Loeb, Katherine Amin MD

MAY 2025

PD05-11:SINGLE INSTITUTION COMPARISON OF MESH SACROCOLPOPEXY USE BETWEEN UROLOGY AND GYNECOLOGY TRAINED UROGYNECOLOGISTS FOR THE TREATMENT OF APICAL PROLAPSE IN ELDERLY PATIENTS

Amy Ruomei Wu, Tamar Yacoel, Alan Wein, Katherine Amin, and Raveen Syan

MAY 2025

IP25-04: ASSESSING INFLUENCE OF PHYSICIAN GENDER CONGRUENCE AND LANGUAGE INTERPRETER SERVICES IN UROLOGY

Grace K. Sarris, Max D. Sandler, Adam Williams, Katherine Amin, Alan J. Wein, and Raveen Syan

MAY 2025

MP06-03: SURGICAL INTELLIGENCE AND LARGE LANGUAGE MODELS: LEVERAGING AI FOR COMPLETE AND ACCURATE OPERATIVE REPORTING

Archan Khandekar, Hemendra Shah, Pedro Freitas, Yariv Colbeci, Dotan Asselmann, Tamir Wolf, Ansh Bhatia, Jonathan Katz, Bruno Nahar, Chad Ritch, Sanoj Punnen, Mark L. Gonzalgo, and Dipen J. Parekh

MAY 2025

IP06-15: EXPLORING THE MICROBIOME OF THE RENAL PAPILLA IN CALCIUM OXALATE STONE FORMERS: PILOTRESULTS FROM FIRST HUMAN STUDY

Sabika Sadiq, Joao G. Porto, Aravindh Rathinam, Oleksandr Kryvenko, Sabita Roy, Jonathan Katz, Robert Marcovich, and Hemendra Shah

MAY 2025

IP05-08: INTEGRATIVE MULTI-OMIC ANALYSIS OF EXTRACELLULAR VESICLE TRANSCRIPTOMICS PROFILING COMBINED WITH CFDNA METHYLATION REVEALS IMPROVED STRATIFICATION OF LOW-RISK AND HIGH-RISK PROSTATE CANCER PATIENTS IN URINE-BASED LIQUID BIOPSY

Omri Nativ, Gareth Reid, Sudipto K. Chakrabortty, Dulaney Miller, Kyle Manning, Rikky Xing, Jeff Cole, Christopher Benway, Sinead Nguyen, Allan George, Yiyuan Yao, Elena M. Cortizas, Miami, Fl, Christian Ray, Siva Gowrisankar, Seth Yu, Allan Pollack, Sandra M. Gaston, Sanoj Punnen, and Johan Skog

MAY 2025

IP03-40: EVALUATING THE SAFETY AND EFFICACY OF EN-BLOC HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN PATIENTS WITH A HISTORY OF RADIATION THERAPY OR HIGH FREQUENCY FOCUSED ULTRASOUND FOR MANAGEMENT OF ORGAN CONFINED PROSTATE CANCER

Adele Raymo, Ansh Bhatia, Archan Khandekar, Aravindh Rathinam, Joao G. Porto, Jean Carlo Daher, Jonathan Elliott Katz, Robert Marcovich, and Hemendra N. Shah

MAY 2025

IP21-04: EXPLORING PROSTATE-SPECIFIC ANTIGEN TESTING RATES AND SCREENING DISPARITIES IN THE ALL OF US DATASET

Jonathan T. Ryan, William Jin, Joao G. Porto, Dinno Mendiola, Tarek Ajami, Hui Yu, Brandon Mahal, and Sanoj Punnen

MAY 2025

MP10-06: VALIDATION OF PAM50 AND PSC GENOMIC CLASSIFIER SYSTEMS FOR PREDICTING PROSTATE CANCER PROGRESSION IN ACTIVE SURVEILLANCE: RESULTS FROM THE MIAMI MAST PROSPECTIVE CLINICAL TRIAL

Ankur Malpani, Jonathan T. Ryan, Hui Yu, Joao G. Porto, Nachiketh Soodana-Prakash, Archan Khandekar, Tarek Ajami, Elena Cortizas, Timothy Gerard, Zoe Szczotka, Elai Davicioni, Mohammed Alshalalfa, Yangyang Hao, Sanjaya Swain, Oleksandr Kryvenko, Alan Dal Pra, Radka Stoyanova, Sandra Gaston, Alan Pollack, Brandon Mahal, Matthew Abramowitz, Bruno Nahar, Chad R. Ritch, Mark L. Gonzalgo, Dipen J. Parekh, and Sanoj Punnen

MAY 2025

MP33-10: LEVERAGING AUGMENTED REALITY TO ELEVATE PATIENT UNDERSTANDING AND SATISFACTION WITH RENAL MASS IMAGING: INSIGHTS FROM A PROSPECTIVE STUDY

Archan Khandekar, Timothy Guerard, Pedro Freitas, Elena Cortizas, Adam Williams, Zoe Szczotka, Hemendra Shah, Jonathan Katz, Bruno Nahar, Sanoj Punnen, Chad Ritch, Mark L. Gonzalgo, and Dipen J. Parekh

MAY 2025

PD18-06: RACIAL AND ETHNIC DISPARITIES IN THE UTILIZATION OF MINIMALLY INVASIVE AND NEPHRON-SPARING SURGERIES FOR RENAL CELL CARCINOMA

Pablo E. Puente, Pedro F. Freitas, Adam D. Williams, Sanoj Punnen, Bruno Nahar, Chad R. Ritch, Dipen J. Parekh, and Mark L. Gonzalgo

MAY 2025

MP10-13: CAN GENOMIC CLASSIFIERS IN BIOPSY CORES WITH GRADE GROUP 1 CANCER PREDICT HIGHER-GRADE DISEASE ELSEWHERE IN THE PROSTATE? RESULTS FROM THE MIAMI ACTIVE SURVEILLANCE TRIAL

Pedro F. S. Freitas, Archan Khandekar, Joao Porto, Hui Yu, Yuval Avda, Ankur Malpani, Tarek F. Ajami, Dinno F. Mendiola, Nachiketh Soodana-Prakash, Sanjaya Swain, Sandra Gaston, Brandon Mahal, Elena Cortizas, Zoe Szczotka, Timothy Guerard, Bruce Kava, Radka Stoyanova, Chad R. Ritch, Bruno Nahar, Mark L. Gonzalgo, Alan Pollack, Dipen Parekh, and Sanoj Punnen

MAY 2025

IP06-10: HARNESSING NATURAL LANGUAGE PROCESSING TO EXTRACT STONE COMPOSITION DATA FROM EXTERNAL PDF FILES AND EXAMINE RELATIONSHIPS WITH PATIENT EMR DATA: A NOVEL LLM-BASED METHODOLOGY

Archan Khandekar, Joshua Mondshine, Pedro Freitas, Ansh Bhatia, Jonathan Katz, Hemendra Shah, Maritza M. Suarez, Robert Marcovich, and Dipen J. Parekh

MAY 2025

PD21-13: SIMULATED KIDNEY AND KIDNEY STONE TO EVALUATE OPTIMAL POSITIONING TO MINIMIZE STONE MIGRATION DURING URETEROSCOPY

Ashley Gordon, Orlando Diaz-Ramos, Aravind Rathinam, Archan Khandekar, Hemendra Shah, Robert Marcovich, Julio Ojalvo, Sarvesh Saini, Ubbo Visser, Francesco Alessandrino, and Jonathan Katz

MAY 2025

UCF-18: GLOBAL VARIATIONS IN TRANSURETHRAL RESECTION OF THE PROSTATE OUTCOMES IN THE 21ST CENTURY: A SYSTEMATIC REVIEW AND META-ANALYSIS

Sabika Sadiq, Joao G. Porto, Aravindh Rathinam, Jonathan Katz, Robert Marcovich, and Hemendra Shah

MAY 2025

MP24-20: EXAMINING TREATMENT OUTCOMES IN PATIENTS WITH CONCOMITTANT STRESS URINARY INCONTINENCE AND SYMPTOMATIC DETRUSOR UNDERACTIVITY

Mary Rostom, Suyen Vilchez, Alan Wein, Adam Williams, Raveen Syan, and Katherine Amin

MAY 2025

IP18-31: GLANS NECROSIS FOLLOWING INFLATABLE PENILE PROSTHESIS IMPLANTATION IN A PATIENT WITH TYPE I MUSCULAR DYSTROPHY

Etienne Gozlan, Jordan Best, and Laura Horodyski

SESAUA

MAR 2025

PODIUM #17: ASSESSING HEMATURIA SCREENING DISPARITIES USING THE ALL OF US DATABASE

Jonathan Ryan1, William Jin2, Dinno Mendiola3, Laura Angulo Llanos3, Hui Yu4, Brandon Mahal2, Sanoj Punnen3

MAR 2025

PODIUM #18: VALIDATION OF PAM50 FOR PREDICTING PROGRESSION IN ACTIVE SURVEILLANCE: RESULTS FROM THE MIAMI MAST PROSPECTIVE CLINICAL TRIAL

Jamie Thomas1, Ankur Malpani1, Jonathan Ryan1, Hui Yu1, Joao Porto1, Nachiketh Soodana-Prakash1, Archan Khandekar1, Tarek Ajami1, Elena Cortizas1, Timothy Guerard1, Zoe Szczotka1, Sanjaya Swain1, Oleksandr Kryvenko2, Alan Dal Pra3, Radka Stoyanova3, Sandra Gaston3, Alan Pollack3, Brandon Mahal3, Matthew Abramowitz3, Bruno Nahar1, Chad Ritch1, Bruce Kava1, Mark Gonzalgo1, Dipen Parekh1, Sanoj Punnen1

MAR 2025

POSTER #10: EXPLORING PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING RATES AND SCREENING DISPARITIES IN THE ALL OF US DATASET

Jonathan Ryan1, William Jin2, Joao Porto3, Dinno Mendiola3, Tarek Ajami3, Hui Yu4, Brandon Mahal2, Sanoj Punnen3

MAR 2025

POSTER #18: PERFORMANCE OF MULTIPARAMETRIC MRI IN ACTIVE SURVEILLANCE OF PROSTATE CANCER: MIAMI MAST TRIAL

Jessica Delgado, Nachiketh Soodana-Prakash, Sunwoo Han, Isildinha Reis, Pedro Freitas, Ruben Blachman-Braun, Jaime Thomas, Chad Ritch, Mark Gonzalgo, Bruno Nahar, Radka Stoyanova, Sanoj Punnen, Alan Pollack, Dipen Parekh

MAR 2025

POSTER #26: ASSESSING MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL

Tarek Ajami, MD1, Nachiketh Soodana Prakesh, MD1, Joao Porto, MD1, Yuval Avda, MD1, Ankur Malpani, MD1, Dinno Mendiola, MD1, Pedro Freitas, MD1, Archan Khandekar, MD1, Sanjaya Swain, MD1, Zoe Szczotka, BS1, Sandra Gaston, PhD1, Brandon Mahal, MD2, Elena Cortizas, MS, ACRP1, Timothy Gerard, BS1, Bruce Kava, MD1, Radka stoyanova, MD3, Allan Pollock, MD3, Dipen Parekh, MD1, Mary Rostom, MD1, Chad Ritch, MD1, Bruno Nahar, MD1, Mark Gonzalgo, MD1, Sanoj Punnen, MD1

MAR 2025

PODIUM #30: SIMULATED KIDNEY AND KIDNEY STONE TO EVALUATE OPTIMAL POSITIONING FOR URETEROSCOPY

Ashley Gordon1, Orlando Diaz-Ramos1, Hemendra Shah1, Robert Marcovich1, Julio Ojalvo2, Sarvesh Saini2, Ubbo Visser2, Jonathan Katz1

MAR 2025

PODIUM #79: STRESS URINARY INCONTINENCE TREATMENT WITH BULKAMID®: OUTCOMES FROM AN ACADEMIC TRAINING INSTITUTION

Max Sandler, BS, Faaris Khan, BS, Veronica Junco, BS, Adam Williams, MSc, Katherine Amin, MD, Alan Wein, MD, Raveen Syan, MD

MAR 2025

PODIUM #82: SURVEY OF PATIENTS WITH OVERACTIVE BLADDER USING GLP-1 AGONISTS

Max Sandler, BS, Adam Williams, MSc, Katherine Amin, MD, Alan Wein, MD, Raveen Syan, MD

MAR 2025

POSTER #58: ARE ABNORMAL VASECTOMY PATHOLOGY REPORTS PREDICTIVE OF PROCEDURAL FAILURE?

Max Sandler, BS, Laura Angulo-Llanos, MD, Rohan Dureja, BS MHA, Adriana Sandino, BS, Faaris Khan, BS, Dan Tran, BS, Veronica Junco, Julio Yanes, BS MS, Thomas Masterson, MD

SMSNA

OCT 2024

COMPARATIVE OUTCOMES OF PHOSPHODIESTERASE 5 INHIBITORS AND COLLAGENASE CLOSTRIDIUM HISTOLYTICUM VS. COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ALONE FOR MANAGEMENT OF PEYRONIE’S DISEASE: A MULTICENTER RETROSPECTIVE CHART REVIEW (#034)

Angulo-Llanos, L; Garrett, GM; Sandler, MD; Tran, DV; Saffati Grunhaus, G; Orozco Rendon, D; Hinojosa-Gonzalez, DE; Kronstedt, S; Miller, JA; Moukhtar Hammad, MA; Yafi, FA; Khera, M; Raheem, O; Masterson, TA

OCT 2024

CORRELATION BETWEEN BIOPSY FREQUENCY AND REDUCED SEXUAL FUNCTION IN PROSTATE CANCER PATIENTS UNDER ACTIVE SURVEILLANCE: A PROSPECTIVE COHORT STUDY (#128)

Cortizas, EM; Angulo-Llanos, L; Szczotka, ZO; Williams, AD; Guerard, T; Punnen, S; Masterson, TA

OCT 2024

SATISFACTION AFTER COLLAGENASE CLOSTRIDIUM HISTOLYTICUM MAY BE IMPACTED BY THE ACCURACY OF PATIENT-PREDICTED PENILE CURVATURE (#038)

J Miller, M Hammad, G Saffati Grunhaus, D Rendon, D Hinojosa-Gonzalez, S Kronstedt, L Angulo-Llanos, G Garrett, M Sandler, D Tran, O Raheem, T Masterson, M Khera, F Yafi

OCT 2024

MULTI-CENTER RETROSPECTIVE STUDY ON THE IMPACT OF TESTOSTERONE ON PENILE CURVATURE IN PATIENTS WITH PEYRONIE’S DISEASE UNDERGOING COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT (#040)

Orozco Rendon , D; Saffati, G1; Hinojosa-Gonzalez, D; Kronstedt, S1; Miller, J; Moukhtar Hammad, MA; Yafi, F; Angulo-Llanos, L; Garrett, G; Sandler, M; Tran, D; Masterson, T; Raheem, O; Khera, M

OCT 2024

EFFICACY AND SAFETY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT IN PATIENTS WITH VENTRAL PENILE PLAQUES (#035)

G Saffati, D Orozco Rendon, DE Hinojosa-Gonzalez, S Kronstedt, JA Miller, MA Moukhtar Hammad, FA Yafi, L Angulo-Llanos, GM Garret, MD Sandler, DV Tran, TA Masterson, O Raheem, M Khera

SUO

DEC 2024

POSTER # 18: ASSESSING HEMATURIA SCREENING DISPARITIES USING THE ALL OF US DATABASE

Jonathan T. Ryan, William Jin, Dinno Mendiola, Tarek Ajami, Hui Yu, Brandon Mahal, and Sanoj Punnen

DEC 2024

POSTER #58: NATIONAL REGISTRY ANALYSIS OF EPIDEMIOLOGY, TRENDS IN TREATMENT AND OUTCOMES OF RENAL SARCOMAS

Sabika Sadiq Tarek Ajami Adam Williams Yuval Avda Ruben Blachmann Sanoj Punnen Bruno Nahar Mark L. Gonzalgo Dipen J. Parekh Chad R. Ritch

DEC 2024

POSTER #75: EVALUATING TREATMENT APPROACHES FOR PRIMARY PROSTATE SARCOMA: A NATIONAL REGISTRY ANALYSIS

Jessica Delgado Ruben Blachman-Braun Sabika Sadkiq Yuval Avda Adam Williams Tarek Ajami Mark L Gonzalgo Bruno Nahar Sanoj Punnen Dipen J Parekh Chad R Ritch

DEC 2024

POSTER #192: CAN GENOMIC CLASSIFIERS IN BIOPSY CORES WITH GRADE GROUP 1 CANCER PREDICT HIGHER-GRADE DISEASE ELSEWHERE IN THE PROSTATE? RESULTS FROM THE MIAMI ACTIVE SURVEILLANCE TRIAL

Pedro Freitas Archan Khandekar Joao Porto Hui Yu Yuval Avda Ankur Malpani Tarek Ajami Dinno F. Mendiola Nachiketh Soodana-Prakash Sanjaya Swain Sandra Gaston Brandon Mahal Elena Cortizas Zoe Szczotka Timothy Guerard Bruce Kava Radka Stoyanova Chad Ritch Bruno Nahar Mark Gonzalgo Alan Pollack Dipen Parekh Sanoj Punnen

DEC 2024

POSTER #220: USE OF BIOCHEMICAL AND IMAGING CRITERIA FOR SELECTING PATIENTS FOR PROSTATE BIOPSY IN RECURRENCE RISK ASSESSMENT POST-HIFU THERAPY

Tarek Ajami Joao Porto Nachiketh Soodana Prakash Adam Williams Archan Khandekar Ankur Malpani Chad Ritch Sanoj Punnen Mark Gonzalgo Dipen J. Parekh Bruno Nahar

Publications

Academic Radiology

DEC 2024

HRS IMPROVES ACTIVE SURVEILLANCE FOR PROSTATE CANCER BY TIMELY IDENTIFICATION OF PROGRESSION

Isabella M. Kimbel, Veronica Wallaengen, Evangelia I. Zacharaki, Adrian L. Breto, Ahmad Algohary, Sophia Carbohn, Sandra M. Gaston, Nachiketh Soodana-Prakash, Pedro F.S. Freitas, Oleksandr N. Kryvenko, Patricia Castillo, Matthew C. Abramowitz, Chad R. Ritch, Bruno Nahar, Mark L. Gonzalgo, Dipen J. Parekh, Alan Pollack, Sanoj Punnen, Radka Stoyanova

Andrology

MAR 2025

LOST TO FOLLOW UP: SEMEN ANALYSIS COMPLIANCE FOLLOWING POTENTIAL VASECTOMY FAILURE

Max D. Sandler, Laura Angulo-Llanos, Rohan Dureja, Faaris Khan, Adriana Sandino, Veronica Junco, Dan V. Tran, Julio Yanes, Adam D. Williams, Thomas A. Masterson

bioRxiv

DEC 2024

TARGETING ENDOPLASMIC RETICULUM STRESS AND NITROSO-REDOX IMBALANCE IN NEUROENDOCRINE PROSTATE CANCER: THE THERAPEUTIC ROLE OF NITRIC OXIDE

Fakiha Firdaus, Osmel Companioni Napoles, Rehana Qureshi, Raul Ariel Dulce, Anusha Edupuganti, Surinder Kumar, Khushi Shah, Salih Salihoglu, Derek J Van Booven, Richard Gasca, Sanoj Punnen, David Lombard, Joshua M. Hare, Himanshu Arora

BJUI Compass

OCT 2024

ACCURACY OF WARM ISCHEMIA TIME MEASUREMENT USING A SURGICAL INTELLIGENCE SOFTWARE IN PARTIAL NEPHRECTOMIES: A VALIDATION STUDY

Archan Khandekar, Joao G. Porto, Jean C. Daher, Pedro F. S. Freitas, Dotan Asselman, Maritza M. Suarez, Mark L. Gonzalgo, Dipen J. Parekh, Sanoj Punnen

OCT 2024

COMPARING OUTCOMES OF AQUABLATION VERSUS HOLMIUM LASER ENUCLEATION OF PROSTATE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A NETWORK META-ANALYSIS

Ansh Bhatia, Renil Titus, Joao G. Porto, Rajvi Goradia, Khushi Shah, Diana Lopategui, Thomas R. W. Herrmann, Hemendra N. Shah

DEC 2024

SAFETY AND FEASIBILITY OF EN-BLOC HOLMIUM LASER ENUCLEATION FOR VERY LARGE PROSTATES (> 200 CC) WITH TRAINEE INVOLVEMENT

Feres C Maluf 1, Ansh Bhatia 2, Archan Khandekar 2, Diana M Lopategui 2, Joao G Porto 2, Ryan R Chen 2, Jean C Daher 2, Mohamadhusni Zarli 3, Robert Marcovich 2, Hemendra N Shah

MAY 2025

A PROSPECTIVE ANALYSIS OF URETERAL STENTING DURING RADICAL CYSTECTOMY AND ILEAL CONDUIT URINARY DIVERSION: PAEDIATRIC FEEDING TUBES VERSUS SINGLE-J STENTS

Jonathan T. Ryan, Tarek Ajami, Adam Williams, Dinno Mendiola, Bruno Nahar, Sanoj Punnen, Chad R. Ritch, Dipen J. Parekh, Mark L. Gonzalgo

Case Reports in Surgery

MAY 2025

TRANSURETHRAL TREATMENT OF A SEMINAL VESICLE CYST WITH LITHIASIS: CASE REPORT

Mohamadhusni Zarli, Joao G. Porto, Ruben Blachman-Braun, Hemendra Shah

Case Reports in Urology

JUN 2024

CHONDROMA IN THE URINARY BLADDER: AN EXTREMELY RARE FINDING

Joao G. Porto, Ruben Blachman-Braun, Archan Khandekar, Oleksandr N. Kryvenko, Dipen J. Parekh

NOV 2024

UNUSUAL METASTASIS OF PANCREATIC ADENOCARCINOMA INTO THE BLADDER: TWO CASE REPORTS AND LITERATURE REVIEW

Mohamadhusni Zarli, Joao G. Porto, Ruben Blachman-Braun, Oleksandr N. Kryvenko, Hemendra N. Shah

Cell Reports Medicine

AUG 2024

HSD3B1 GENOTYPE AND OUTCOMES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH ANDROGEN DEPRIVATION THERAPY AND ENZALUTAMIDE: ARCHES

Sharifi, Nima and Azad, Arun A. and Patel, Mona and Hearn, Jason W. D. and Wozniak, Michele and Zohren, Fabian and Sugg, Jennifer and Haas, Gabriel P. and Stenzl, Arnulf and Armstrong, Andrew J.

Clinical Genitourinary Cancer

DEC 2024

IMPACT OF BMI CATEGORY ON RECURRENCE AND PROGRESSION OF NON-MUSCLE INVASIVE BLADDER CANCER PROGNOSIS

Jamie Thomas, Aakangsha Jain, Ram Hirpara, Ruben Blachman-Braun, Helen Y. Hougen, Nachiketh Soodana-Prakash, Maria C. Velasquez, Tarek Ajami, Bruno Nahar, Mark L. Gonzalgo, Bruce Kava, Sanoj Punnen, Dipen J. Parekh, Chad R. Ritch

Continence Reports

MAY 2025

EFFECTS OF GLUCAGON LIKE PEPTIDE-1 AGONISTS ON PATIENTS WITH OVERACTIVE BLADDER: A PILOT STUDY

Max D. Sandler, Adam D. Williams, Alan Wein, Katherine Amin, Raveen Syan

Cureus

OCT 2024

SNIP, SUPPORT, AND SHARED STORIES: EXPLORING REDDIT USERS' EXPERIENCES WITH VASECTOMY

Max D. Sandler, Jordan C. Best, Mary K. Samplaski, Armin Ghomeshi, Thomas A. Masterson

DEC 2024

OVERCOMING CHALLENGES IN RETRIEVING AN ENCAPSULATED REAR TIP EXTENSOR DURING CONVERSION FROM MALLEABLE TO INFLATABLE PENILE PROSTHESIS SURGERY: A CASE REPORT AND REVIEW OF LITERATURE

Laura Angulo-Llanos, Armin Ghomeshi, Thomas Masterson

European Urology Focus

NOV 2024

SURVIVAL OUTCOMES AND RECURRENCE PATTERNS FOLLOWING FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND TREATMENT FOR LOCALIZED PROSTATE CANCER: INSIGHTS ON PATIENT SELECTION AND LESSONS LEARNED

Nahar, Bruno and Ajami, Tarek and Williams, Adam and Soodana Prakash, Nachiketh and Khandekar, Archan and Freitas, Pedro F. S. and Malpani, Ankur and Ryan, Jonathan T. and Sureshkumar, Keerthana and Ritch, Chad R. and Gonzalgo, Mark L. and Punnen, Sanoj and Parekh, Dipen J.

DEC 2024

ASSESSING THE MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL

Ajami, Tarek and Yu, Hui and Porto, Joao G. and Prakash, Nachiketh Soodana and Williams, Adam and Avda, Yuval and Malpani, Ankur and Mendiola, Dinno F. and Freitas, Pedro F. S. and Khandekar, Archan and Swain, Sanjaya and Gaston, Sandra and Mahal, Brandon and Cortizas, Elena and Szczotka, Zoe and Gerard, Timothy and Kava, Bruce and Stoyanova, Radka and Kryvenko, Oleksandr N. and Castillo, Patricia and Ritch, Chad R. and Nahar, Bruno and Gonzalgo, Mark L. and Pollack, Alan and Parekh, Dipen J. and Punnen, Sanoj

Fertility and Sterility

OCT 2024

COMPLIANCE OF SEMEN TESTING IN MEN AFTER POTENTIAL VASECTOMY FAILURE

Sandler, Max D. and Llanos, Laura Angulo and Williams, Adam D. and Khan, Faaris and Sandino, Adriana and Tran, Dan and Dureja, Rohan and Yanes, Julio and Junco, Veronica and Masterson, Thomas A., III

Journal of Clinical Oncology

FEB 2025

GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL

David J Lee, Tarek Ajami, Hui Yu, Nachiketh Soodana-Prakash, Joao Porto, Yuval Avda, Ankur Malpani, Dinno F Mendiola, Pedro F.S. Freitas, Archan Khandekar, Sanjaya Swain, Sandra M. Gaston, Brandon A. Mahal, and Sanoj Punnen

FEB 2025

ASSESSING MOLECULAR HETEROGENEITY OF PROSTATE CANCER BIOPSY SAMPLING: INSIGHTS FROM THE MAST TRIAL.

David J Lee, Brandon A. Mahal, Sanoj Punnen

FEB 2025

VALIDATION OF PAM50 FOR PREDICTING PROGRESSION IN ACTIVE SURVEILLANCE: RESULTS FROM THE MIAMI MAST PROSPECTIVE CLINICAL TRIAL.

David J Lee, Brandon A. Mahal, Sanoj Punnen

FEB 2025

GENE EXPRESSION SIGNATURES IN BIOPSY CORES AS PREDICTORS OF COEXISTING HIGHER-GRADE DISEASE IN GLEASON GROUP 1 PROSTATE CANCER: RESULTS FROM THE MIAMI MAST PROSPECTIVE CLINICAL TRIAL.

David J Lee, Brandon A. Mahal, Sanoj Punnen

FEB 2025

ADRENAL ANDROGENS AND OVERALL SURVIVAL (OS) IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH ENZALUTAMIDE WITHOUT (ENZ) OR WITH ABIRATERONE AND PREDNISONE (ENZ/ AAP) (ALLIANCE)

Nima Sharifi, Hyotae Kim, Mohammad Alyamani, Robert Diaz, Himisha Beltran, Andrew J. Armstrong, Michael J. Morris, Susan Halabi, and Charles J. Ryan

FEB 2025

HSD3B1 AND OVERALL SURVIVAL (OS) IN HIGH-RISK NON-METASTATIC (M0) AND METASTATIC (M1) PROSTATE CANCER STARTING ANDROGEN DEPRIVATION THERAPY (ADT) IN THE ENZALUTAMIDE (ENZ) AND ABIRATERONE ACETATE PLUS PREDNISOLONE (AAP) STAMPEDE PHASE 3 TRIAL.

Nima Sharifi, Mahaz Kayani, Laura Murphy, Robert Diaz, Emily Grist, Zsofia Kote-Jarai, Ros A. Eeles, Gianmarco Leone, Noel W Clarke, Mahesh K. B. Parmar, Louise C. Brown, Nicholas David James, and Gerhardt Attard

Journal of Personalized Medicine

JUN 2024

SYNTHETIC GENITOURINARY IMAGE SYNTHESIS VIA GENERATIVE ADVERSARIAL NETWORKS: ENHANCING ARTIFICIAL INTELLIGENCE DIAGNOSTIC PRECISION

Derek J. Van Booven 1,Cheng-Bang Chen 2,Sheetal Malpani 3,Yasamin Mirzabeigi 3,Maral Mohammadi 4,Yujie Wang 2,Oleksander N. Kryvenko 3,Sanoj Punnen 5 andHimanshu Arora

Journal of Sexual Medicine

DEC 2024

(128) CORRELATION BETWEEN BIOPSY FREQUENCY AND REDUCED SEXUAL FUNCTION IN PROSTATE CANCER PATIENTS UNDER ACTIVE SURVEILLANCE: A PROSPECTIVE COHORT STUDY

EM Cortizas, L Angulo-Llanos, ZO Szcotka, AD Williams, T Guerard, S Punnen, TA Masterson

DEC 2024

(040) MULTI-CENTER RETROSPECTIVE STUDY ON THE IMPACT OF TESTOSTERONE ON PENILE CURVATURE IN PATIENTS WITH PEYRONIE’S DISEASE UNDERGOING COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT

D Orozco Rendon, G Saffati, D Hinojosa-Gonzalez, S Kronstedt, J Miller, MA Moukhtar Hammad, F Yafi, L Angulo-Llanos, G Garrett, M Sandler, D Tran, T Masterson, O Raheem, M Khera

DEC 2024

(038) SATISFACTION AFTER COLLAGENASE CLOSTRIDIUM HISTOLYTICUM MAY BE IMPACTED BY THE ACCURACY OF PATIENT-PREDICTED PENILE CURVATURE

J Miller, M Hammad, G Saffati Grunhaus, D Rendon, D Hinojosa-Gonzalez, S Kronstedt, L Angulo-Llanos, G Garrett, M Sandler, D Tran, O Raheem, T Masterson, M Khera, F Yafi

DEC 2024

(055) HEAVY METAL EXPOSURE AND ERECTILE DYSFUNCTION: INSIGHTS FROM THE ALL OF US RESEARCH PROGRAM

J Ryan, L Angulo-Llanos, H Yu, S Punnen, T Masterson

DEC 2024

(034) COMPARATIVE OUTCOMES OF PHOSPHODIESTERASE 5 INHIBITORS AND COLLAGENASE CLOSTRIDIUM HISTOLYTICUM VS. COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ALONE FOR MANAGEMENT OF PEYRONIE’S DISEASE: A MULTICENTER RETROSPECTIVE CHART REVIEW

L Angulo-Llanos, GM Garrett, MD Sandler, DV Tran, G Saffati Grunhaus, D Orozco Rendon, DE Hinojosa-Gonzalez, S Kronstedt, JA Miller, MA Moukhtar Hammad, FA Yafi, M Khera, O Raheem, TA Masterson

DEC 2024

(107) A PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER TRIAL TO EVALUATE SAFETY AND EFFICACY OF PLATELET-RICH PLASMA INJECTIONS FOR PEYRONIE’S DISEASE: CLINICAL TRIAL UPDATE

F Costantini Mesquita, D Velasquez, B Ledesma, E Ibrahim, R Ramasamy, T Masterson, S Han, I M Reis, R Saltzman, M Molina

DEC 2024

(035) EFFICACY AND SAFETY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TREATMENT IN PATIENTS WITH VENTRAL PENILE PLAQUES

G Saffati, D Orozco Rendon, DE Hinojosa-Gonzalez, S Kronstedt, JA Miller, MA Moukhtar Hammad, FA Yafi, L Angulo-Llanos, GM Garret, MD Sandler, DV Tran, TA Masterson, O Raheem, M Khera

DEC 2024

(246) SNIP, SUPPORT, AND SHARED STORIES: EXPLORING MEN’S EXPERIENCES WITH VASECTOMY THROUGH AN ONLINE FORUM

Max D. Sandler, J Best, T Masterson

Journal of Vascular and Interventional Radiology

NOV 2024

PROSTATE ARTERY EMBOLIZATION – MID TO LONG-TERM OUTCOMES IN 1075 PATIENTS

Shivank Bhatia, Ansh Bhatia, Andrew J. Richardson, Kenneth Richardson, Chloe Issa, Jessica G. Kumar, Hamed Jalaiean, Bruce Kava, Hemendra N. Shah

Journal of Endourology

OCT 2024

DIGITAL FLEXIBLE URETEROSCOPE: EVALUATING FACTORS RESPONSIBLE FOR DAMAGE AND IMPLEMENTING A MANDATORY CERTIFICATION PROGRAM FOR USAGE

Joao G. Porto, Ansh Bhatia, Renil S. Titus, Maria Camila Suarez Arbelaez, Mohamadhuni Zarti, Alejandra Guevara, Michael Tradewell, Diana M. Lopategui, Ramgopal Satyanarayana, Robert Marcovich, and Hemendra N. Shah

JAN 2025

GRAND STUDY SHOULD NOT PROHIBIT UROLOGISTS FROM OFFERING BILATERAL SAME SESSION URETEROSCOPY TO APPROPRIATE PATIENTS WITH BILATERAL UROLITHIASIS

Ansh Bhatia, Joao G. Porto, Archan Khandekar, Diana M. Lopategui, Robert Marcovich, and Hemendra N. Shah

Lasers in Medical Science

SEP 2024

SIMULTANEOUS THULIUM LASER RESECTION OF THE PROSTATE AND TRANSPERINEAL PROSTATE BIOPSY IN CLINICALLY DIAGNOSED METASTATIC PROSTATE CANCER WITH BLADDER OUTLET OBSTRUCTION: WHY HURRY?

Renil S. Titus, Ansh Bhatia, Joao G. Porto, Diana M. Lopategui, Robert Marcovich & Hemendra N. Shah

JAN 2025

RESECTION OF SIGMOID CANCER WITH BLADDER INVASION USING LAPAROSCOPIC COMBINED WITH A CYSTOSCOPIC HOLMIUM LASER: COMMENT.

Bhatia A, Titus RS, Porto JG, Lopategui D, Paluvoi N, Shah HN

Nature Reviews Urology

OCT 2024

PLANT-BASED DIETS AND UROLOGICAL HEALTH

Loeb S, Borin JF, Venigalla G, Narasimman M, Gupta N, Cole AP, Amin KA.

NOV 2024

HSD3B1, PROSTATE CANCER MORTALITY AND MODIFIABLE OUTCOMES

Pedro F. S. Freitas, Alireza Abdshah, Rana R. McKay & Nima Sharifi

Neurourology and Urodynamics

DEC 2024

EXAMINING GENDER REPRESENTATION IN US NEWS AND WORLD REPORT TOP 25 UROLOGY DEPARTMENTS: FEMALE FACULTY HOLD LOWER PROFESSORIAL LEVELS AND PUBLICATION RATES THAN MALE COUNTERPARTS

Venigalla G, Sadiq S, Gurayah AA, Soodana-Prakash N, Martin L, Amin KA, Syan R.

npj Precision Oncology

MAY 2025

MITIGATING BIAS IN PROSTATE CANCER DIAGNOSIS USING SYNTHETIC DATA FOR IMPROVED AI DRIVEN GLEASON GRADING

Derek J. Van Booven, Cheng-Bang Chen, Oleksandr N. Kryvenko, Sanoj Punnen, Victor Sandoval, Sheetal Malpani, Ahmed Noman, Farhan Ismael, Yujie Wang, Rehana Qureshi, Joshua M. Hare & Himanshu Arora

Physics and Imaging in Radiation Oncology

OCT 2024

INTEGRATED FRAMEWORK FOR QUANTITATIVE T2-WEIGHTED MRI ANALYSIS FOLLOWING PROSTATE CANCER RADIOTHERAPY

Evangelia I. Zacharaki, Adrian L. Breto, Ahmad Algohary, Veronica Wallaengen, Sandra M. Gaston, Sanoj Punnen, Patricia Castillo, Pradip M. Pattany, Oleksandr N. Kryvenko, Benjamin Spieler, John C. Ford, Matthew C. Abramowitz, Alan Dal Pra, Alan Pollack, Radka Stoyanova

Prostate Cancer and Prostatic Diseases

SEP 2024

EVALUATING 4KSCORE’S ROLE IN PREDICTING PROGRESSION ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER INDEPENDENTLY OF CLINICAL INFORMATION AND PIRADS SCORE

Helen Y. Hougén, Isildinha M. Reis, Sunwoo Han, Nachiketh Soodana Prakash, Jamie Thomas, Radka Stoyanova, R. Patricia Castillo, Oleksandr N. Kryvenko, Chad R. Ritch, Bruno Nahar, Mark L. Gonzalgo, Sandra M. Gaston, Matthew C. Abramowitz, Alan Dal Pra, Brandon A. Mahal, Alan Pollack, Dipen J. Parekh & Sanoj Punnen

The Journal of Clinical Endocrinology and Metabolism

JUN 2024

POLYCYSTIC OVARY SYNDROME, METABOLIC SYNDROME, AND INFLAMMATION IN THE HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS.

Rao HC, Meyer ML, Kominiarek MA, Daviglus ML, Gallo LC, Cordero C, Syan R, Perreira KM, Talavera GA, Fernández-Rhodes L.

The Journal of Urology

MAR 2025

COMPARISON OF COMPLICATION AND READMISSION RATES BETWEEN ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY: RESULTS FROM THE RANDOMIZED RAZOR CLINICAL TRIAL

Vivek Venkatramani, Isildinha M. Reis, Mark L. Gonzalgo, Sanjaya Swain, Robert S. Svatek, and Dipen J. Parekh

The Journal of Clinical Investigation

SEP 2024

SURVIVAL OF MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AND ADRENAL-PERMISSIVE HSD3B1 INHERITANCE

Nima Sharifi,1,2 Robert Diaz,1,2 Hui-Ming Lin,3,4 Evan Roberts,1,2 Lisa G. Horvath,3,4,5,6,7 Andrew Martin,7,8,9 Martin R. Stockler,7,8 Sonia Yip,7,8 Vinod V. Subhash,7 Neil Portman,3,4,7 Ian D. Davis,7,10,11 and Christopher J. Sweeney

The World Journal of Mens Health

SEP 2024

FACTORS INFLUENCING CONTINUED USAGE OF INTRACAVERNOSAL INJECTIONS FOR ERECTILE DYSFUNCTION: A RETROSPECTIVE ANALYSIS

Braian Rene Ledesma, Jason Codrington, David Velasquez, Alexandra Aponte Varnum, Joshua White, Greeshma Venigalla, Farah Rahman, Katherine Campbell, Alexander Weber, Max Sandler and Ranjith Ramasamy

Urologic Oncology Seminars and Original Investigations

JUL 2024

MOLECULAR AND DIFFUSION FEATURES FOR IDENTIFICATION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN PI-RADS 3 LESIONS

Tarek Ajami, Sunwoo Han, Joao G. Porto, Isabella Kimbel, Zoe Szczotka, Timothy Guerard, Nathan VanderVeer-Harris, Braian R. Ledesma, Patricia Castillo Acosta, Oleksandr N. Kryvenko, Dipen J. Parekh, Radka Stoyanova, Isildinha M. Reis, Sanoj Punnen

NOV 2024

EXPLORING PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING RATES AND SCREENING DISPARITIES IN THE ALL OF US DATASET

Jonathan T. Ryan, William Jin, Joao G. Porto, Dinno Mendiola, Tarek Ajami, Hui Yu, Brandon A. Mahal, Sanoj Punnen

FEB 2025

ASSOCIATION OF METABOLIC SYNDROME AND CHRONIC KIDNEY DISEASE WITH NONMUSCLE INVASIVE BLADDER CANCER RECURRENCE AND PROGRESSION

Christabel Egemba, Sneha Kapil, Tarek Ajami, Adam Williams, Bruno Nahar, Sanoj Punnen, Dipen J. Parekh, Mark Gonzalgo, Chad R. Ritch

MAR 2025

USE OF BIOCHEMICAL AND IMAGING CRITERIA FOR SELECTING PATIENTS FOR PROSTATE BIOPSY IN RECURRENCE RISK ASSESSMENT POST-HIFU THERAPY

Tarek Ajami, Joao Porto, Nachiketh Soodana Prakash, Adam Williams, Archan Khandekar, Ankur Malpani, Chad Ritch, Sanoj Punnen, Mark Gonzalgo, Dipen Parekh, Bruno Nahar

MAR 2025

NATIONAL REGISTRY ANALYSIS OF EPIDEMIOLOGY, TRENDS IN TREATMENT AND OUTCOMES OF RENAL SARCOMAS

Sabika Sadiq, Tarek Ajami, Adam Williams, Yuval Avda, Ruben Blachmann, Sanoj Punnen, Bruno Nahar, Mark L. Gonzalgo, Dipen J. Parekh, Chad R. Ritch

MAR 2025

EVALUATING TREATMENT APPROACHES FOR PRIMARY PROSTATE SARCOMA: A NATIONAL REGISTRY ANALYSIS

Jessica Delgado, Ruben Blachman-Braun, Sabika Sadkiq, Yuval Avda, Adam Williams, Tarek Ajami, Mark L. Gonzalgo, Bruno Nahar, Sanoj Punnen, Dipen J Parekh, Chad R Ritch

MAR 2025

CAN GENOMIC CLASSIFIERS IN BIOPSY CORES WITH GRADE GROUP 1 CANCER PREDICT HIGHER-GRADE DISEASE ELSEWHERE IN THE PROSTATE? RESULTS FROM THE MIAMI ACTIVE SURVEILLANCE TRIAL

Pedro Freitas, Archan Khandekar, Joao Porto, Hui Yu, Yuval Avda, Ankur Malpani, Tarek Ajami, Dinno Mendiola, Nachiketh Soodana-Prakash, Sanjaya Swain, Sandra Gaston, Brandon Mahal, Elena Cortizas, Zoe Szczotka, Timothy Guerard, Bruce Kava, Radka Stoyanova, Chad Ritch, Bruno Nahar, Mark Gonzalgo, Alan Pollack, Dipen Parekh, Sanoj Punnen

MAR 2025

ASSESSING HEMATURIA SCREENING DISPARITIES USING THE ALL OF US DATABASE

Jonathan T. Ryan, William Jin, Dinno Mendiola, Laura Angulo Llanos, Hui Yu, Brandon Mahal, Sanoj Punnen

Urology

AUG 2024

MINORITY WOMEN UNDERGO SURGICAL TREATMENT OF PELVIC ORGAN PROLAPSE AT SIMILAR RATES TO NON-MINORITIES IN A HISPANIC MINORITY-MAJORITY POPULATION: AN ANALYSIS OF NEARLY 1000 WOMEN.

McHugh EG, Hinkes S, Chisolm A, Nguyen TV, Wein A, Amin K, Williams A, Syan R.

AUG 2024

DOES SEVERITY OF CHRONIC URINARY RETENTION AS ESTIMATED BY PREOPERATIVE RESIDUAL URINE ESTIMATION NEGATIVELY IMPACT THE OUTCOME OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE?

Diana M. Lopategui, Ruben Blachman-Braun, Joao G. Porto, Ansh Bhatia, Robert Marcovich, Hemendra N. Shah

OCT 2024

REPLY TO EDITORIAL COMMENT ON “DOES SEVERITY OF CHRONIC URINARY RETENTION AS ESTIMATED BY PREOPERATIVE RESIDUAL URINE ESTIMATION NEGATIVELY IMPACT THE OUTCOME OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE?”

Lopategui DM, Blachman-Braun R, Porto JG, Bhatia A, Marcovich R, Shah HN.

MAY 2025

EVALUATING PELVIC FLOOR DISORDER CARE AMONG RACIALLY MINORITIZED WOMEN: A FOCUS GROUP ANALYSIS

Greeshma Venigalla 1, Manish Narasimman 1, Sanjana Satish 1, Alan Wein 1, Katherine Amin 1, Natasha Schaefer Solle 2, Raveen Syan

World Journal of Urology

SEP 2024

CHANGING TIMES: TRENDS IN RISK CLASSIFICATION, TUMOR UPSTAGING, AND POSITIVE SURGICAL MARGINS AFTER RADICAL PROSTATECTOMY - RESULTS FROM A CONTEMPORARY NATIONAL CANCER DATABASE STUDY

Pedro F. S. Freitas, Ruben Blachman-Braun, Nachiketh Soodana-Prakash, Adam D. Williams, Chad R. Ritch, Sanoj Punnen, Mark L. Gonzalgo, Dipen Parekh & Bruno Nahar

OCT 2024

EVALUATING THE EFFICACY AND SAFETY OF HOLMIUM LASER ENUCLEATION OF THE PROSTATE IN PATIENTS WITH OBSTRUCTIVE UROPATHY ATTRIBUTABLE TO BLADDER OUTLET OBSTRUCTION

Ansh Bhatia, Joao G. Porto, Renil S. Titus, Jean C. Daher, Theodora M. Zavos, Diana M. Lopategui, Robert Marcovich & Hemendra N. Shah

NOV 2024

OPEN SIMPLE PROSTATECTOMY IN THE LAST THREE DECADES: RESULTS OF A META-ANALYSIS

Renil S. Titus, Ansh Bhatia, Joao G. Porto, Khushi Shah, Diana M. Lopategui, Thomas R. W. Herrmann, Robert Marcovich & Hemendra N. Shah

NOV 2024

EVALUATING TRANSURETHRAL RESECTION OF THE PROSTATE OVER TWENTY YEARS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

Porto JG, Bhatia AM, Bhat A, Suarez Arbelaez MC, Blachman-Braun R, Shah K, Malpani A, Lopategui D, Herrmann TRW, Marcovich R, Shah HN.

DEC 2024

FUNCTIONAL OUTCOMES OF SINGLE-SESSION HOLMIUM LASER ENUCLEATION OF THE PROSTATE AND HIGH-INTENSITY FOCUSED ULTRASOUND IN MANAGEMENT OF PATIENTS WITH PROSTATE CANCER AND ENLARGED PROSTATE: RESULTS FROM A PILOT STUDY

Jessica Delgado, Joao G. Porto, Ansh Bhatia, Adele Raymo, Ruben Blachman-Braun, Tarek Ajami, Aravindh Rathinam, Pedro F. S. Freitas, Archan Khandekar, Robert Marcovich, Dipen J. Parekh, Bruno Nahar & Hemendra N. Shah

JAN 2025

TRANSURETHRAL RESECTION OF THE PROSTATE ACROSS CONTINENTS: A META-ANALYSIS EVALUATING QUALITY OF GOLD STANDARD IN THE TWENTY-FIRST CENTURY

Joao G. Porto, Ansh M. Bhatia, Abhishek Bhat, Maria Camila Suarez Arbelaez, Ruben Blachman-Braun, Khushi Shah, Ankur Malpani, Diana Lopategui, Thomas R. W. Herrmann, Robert Marcovich & Hemendra N. Shah

MAR 2025

USE OF BIOCHEMICAL AND IMAGING CRITERIA FOR SELECTING PATIENTS FOR PROSTATE BIOPSY IN RECURRENCE RISK ASSESSMENT POST-HIFU THERAPY

Tarek Ajami, Adam Williams, Jonathan T. Ryan, Nachiketh Soodana Prakash, Archan Khandekar, Keerthana Sureshkumar, Chad R. Ritch, Mark L. Gonzalgo, Sanoj Punnen, Dipen J. Parekh & Bruno Nahar



DESAI SETHI
UROLOGY INSTITUTE